Established in 1982 as Cardiomyology

ACTA MYOLOGICA

(Myopathies, Cardiomyopathies and Neuromyopathies)

Official Journal of
Mediterranean Society of Myology
and
Associazione Italiana di Miologia

Founders: Giovanni Nigro and Lucia Ines Comi

Three-monthly

EDITORIAL BOARD

Ekram Abdel-Salam, Cairo
Corrado Angelini, Padova
Enrico Bertini, Roma
Serge Braun, Paris
Kate Bushby, Newcastle upon Tyne
Kevin P. Campbell, Iowa City
Marinos Dalakas, Athens
Feza Deymeer, Instanbul
Salvatore Di Mauro, New York
Denis Duboc, Paris
Victor Dubowitz, London
King W. Engel, Los Angeles
Michel Fardeau, Paris
Fayçal Hentati, Tunis
Byron A. Kakulas, Perth
Frank Lehmann-Horn, Ulm
Carlo Minetti, Genova
Clemens Müller, Würzburg
Francesco Muntoni, Londra
Carmen Navarro, Vigo
Gerardo Nigro, Napoli
Anders Oldfors, Göteborg
Ejiro Ozawa, Tokyo
Heinz Reichmann, Dresden
Serenella Servidei, Roma
Piraye Serdaroglu, Instanbul
Yeuda Shapira, Jerusalem
Osman I. Sinanovic, Tuzla
Michael Sinnreich, Montreal
Andoni J. Urtizberea, Hendaye
Gert-Jan van Ommen, Leiden
Lord John Walton of Detchant, Oxford
Steve Wilton, Perth
Klaus Zerres, Aachen
Janez Zidar, Ljubljana
CONTENTS

ORIGINAL ARTICLES

Differential diagnosis of vacuolar muscle biopsies: use of p62, LC3 and LAMP2 immunohistochemistry
Elisa Vittonatto, Silvia Boschi, Loredana Chiadò-Piat, Valentina Ponzalino, Sara Bortolani, Chiara Brusa,
Innocenzo Rainero, Federica Ricci, Liliana Vercelli and Tiziana Mongini ........................................... 191

Study of anti-Müllerian hormone levels in patients with Myotonic Dystrophy Type 1. Preliminary results
Manuela Ergoli, Massimo Venditti, Raffaele Dotolo, Esther Picillo, Sergio Minucci and Luisa Politano .......... 199

The multifaceted clinical presentation of VCP-proteinopathy in a Greek family
George K. Papadimas, George P. Paraskevas, Thomas Zambelis, Chrisostomos Karagiouris, Mara Bourbouli,
Anastasia Bougea, Maggie C. Walter, Nicolas U. Schumacher, Sabine Krause and Elisabeth Kapaki .......... 203

Three new cases of dilated cardiomyopathy caused by mutations in LMNA gene
Larysa N. Sivitskaya, Nina G. Danilenko, Tatiyana G. Vaikhanskaya, Tatsiyana V. Kurushka
and Oleg G. Davydenko .............................................................................................................. 207

CASE REPORTS

Is the epicardial left ventricular lead implantation an alternative approach to percutaneous attempt in patients
with Steinert disease? A case report
Andrea Antonio Papa, Anna Rago, Roberta Petillo, Paola D’Ambrosio, Marianna Scutifero, Marisa De Feo,
Ciro Maiello and Alberto Palladino ................................................................................................. 213

Complete resolution of left atrial appendage thrombosis with oral dabigatran etexilate in a patient with Myotonic
Dystrophy type 1 and atrial fibrillation
Anna Rago, Andrea Antonio Papa, Giulia Arena, Marco Mosella, Antonio Cassese,
Alberto Palladino and Paolo Golino ............................................................................................... 218

OBITUARY

Professor Giovanni Nigro
Luisa Politano and Vincenzo Nigro ................................................................................................. 223

NEWS FROM AROUND THE WORLD

AIM ................................................................................................................................. 225
MSM ............................................................................................................................... 225
WMS ............................................................................................................................... 225

FORTHCOMING MEETINGS ....................................................................................... 226

Volume XXXVI - CONTENTS .................................................................................... 236
Volume XXXVI - AUTHOR INDEX ............................................................................. 238
Volume XXXVI - SUBJECT INDEX ............................................................................... 242
Volume XXXVI - LIST OF REFEREES CONSULTED IN 2017 ........................................ 243

Instructions for Authors ............................................................................................... 245
Intrafibral vacuoles are the morphological hallmark in a wide variety of human skeletal muscle disorders with different etiology. In most cases, differential diagnosis is feasible with a routine histochemical work up of muscle biopsy. Ultrastructural analysis is an important confirmatory tool, but it is not widely available. Immunohistochemical stainings for p62, LAMP2 and LC3 are commonly available as tissutal marker for autophagy. We compared the immunohistochemical patterns for autophagic markers p62, LC3 and LAMP2 with routine histochemical markers in 39 biopsies from patients with definite diagnoses of glycogen storage disease type 2 (LOPD or Pompe disease, PD), sporadic inclusion body myositis (sIBM), oculo-pharyngeal muscular dystrophy (OPMD) and necrotizing myopathy (NM). Moreover, we also analyzed muscles of 10 normal controls. In PD group, LC3 and LAMP2 showed an higher percentage of positive fibers, whereas p62 was limited to a minority of fibers, thus parallelizing the results of histochemical stainings; in NM group, LAMP2 and LC-3 were diffusely and unspecifically expressed in necrotic fibers, with p62 significantly expressed only in two cases. OPMD biopsies did not reveal any significant positivity. The most interesting results were observed in sIBM group, where p62 was expressed in all cases, even in fibers without other markers positivity. There results, although limited to a small number of cases, suggest that the contemporary use of p62, LAMP2 and LC-3 staining may have an adjunctive role in characterizing muscle fiber vacuoles, revealing autophagic pathway activation and providing further clues for the understanding of pathogenetic mechanisms.

Key words: autophagy, Pompe disease, inclusion body myopathy, necrotizing myopathy, immunohistochemistry

Introduction

Autophagy is a highly conserved homeostatic process for lysosome mediated degradation of cytoplasmic components, including damaged organelles and toxic protein aggregates (1). The process of autophagy occurs through a multi-step mechanism, including the formation of a phagophore, which engulfs proteins and organelles destined for degradation, then the production of a membrane-bound vacuole (the autophagosome), which moves along microtubules and fuses with the lysosome to form the autolysosome. Microtubule-associated protein light chain 3 (LC3) is commonly used as a marker of autophagy (2-3). Upon autophagy induction, its modified form LC3-II, associated with autophagic membranes, binds p62/SQSTM1, an adapter protein that targets ubiquitinated protein aggregates (4). The lysosomal-dependent turnover of LC3-II and p62 has emerged as a measure of autophagic proteolysis. Specifically, the accumulation of LC3-II-labeled autophagosomes and/or p62 aggregates is a robust marker of autophagic flux engulfment at any point beyond autophagosome formation (3).

Lysosome-associated membrane protein 2 (LAMP2) is a glycoprotein with a principal role in the adhesion of the lysosome, and therefore in their protection and maintenance studied in human tissues by immunohistochemical markers (5).

Autophagic vacuolar myopathies are a group of muscle disorders characterized by massive autophagic...
buildup. Pompe disease (PD) is due to a defect in lysosomal acid a-glucosidase (GAA), with intralysosomal glycogen accumulation (6); Danon disease is caused by lack of the lysosome associated membrane protein 2 (LAMP2) (7) with increase of dysfunctional lysosomes in skeletal and cardiac muscles; and the X-linked myopathy with excessive autophagy (XMEA) is due to mutations in V-ATPase (8). The exact role of autophagy dysfunction is still debated; however, in a recent work of Nascimbeni at al. (9) other autophagy regulators, like transcription factor EB (TFEB) and vacuolar protein sorting 15 (VPS15), seem to have an active role in the pathogenesis of both Danon disease and PD, showing an autophagy block correlated with the severity of the disease; therefore therapeutic approaches targeted to normalize these factors and restore the autophagic flux should be considered.

Other myopathies are characterized by the presence of intrafibril vacuoles, originated by different pathological processes; these include inclusion body myopathies (IBM), necrotizing myopathies (NM), and ocu planoayngeal muscular dystrophy (OPMD).

IBMs are classified as sporadic (s-IBM), a relatively common inflammatory myopathy classically presenting in older individuals (10-12), and hereditary (h-IBM), caused by gene mutations producing intrafibril protein storage, with disruption of cell architecture (i.e., UDP-N-acetylglucosamine-2 epimerase/N-acetylmannosamine-kinase or GNE gene).

Necrotizing myopathies (NM) have a multifactorial etiology; they may have an acute or subacute onset, can be severe, may have an autoimmune pathogenesis or be associated to cancer, and may be related to statin therapy. Diagnosis is based on the clinical picture and on muscle biopsy showing minimal or no inflammatory infiltrates and marked muscle necrosis with vacuolated fibers and macrophagic activation, unlike other inflammatory myopathies (10).

Ocu planoayngeal muscular dystrophy (OPMD) is a late-onset muscle disease associated with progressive ptosis of the eyelids, dysphagia, and unique histological features, including intracytoplasmic rimmed vacuoles and tubule-filamentous intranuclear inclusions (INIs) in skeletal muscle. Polyalanine [poly(A)] expansion mutations in the polyadenine-binding protein 2 (PABN1) gene have been shown to cause OPMD (11). Since its impairment leads to accumulation of autophagosomes, autophagy can be detected by immunohistochemistry for autophagy proteins LC3 and p62/SQSTM1; immunostaining for either LC3 or p62 was proposed to replace electron microscopy in the diagnosis of autophagic vacuolar myopathies (12-15).

LC3 and p62 have also been evaluated as markers of IBM (16).

In routinary muscle biopsy evaluation, differential diagnosis of vacuolar myopathies can be challenging for the presence of only mild alterations, or unspecific/unrelated tissue changes; moreover, in some cases clinical data may lack or are only partially supportive. Aim of this retrospective study is to verify the use of a simple immunohistochemical procedure to detect autophagic activation in a series of muscle biopsies with a defined diagnosis of vacuolar myopathy, in order to ameliorate the diagnostic accuracy.

**Materials and methods**

**Ethics statement**

All patients had undergone quadriceps muscle biopsy for diagnostic purposes, and signed full informed consent. No individually identifiable patient data are presented in this report.

**Objectives**

This is a retrospective study on muscle tissue samples stored in liquid nitrogen from patients affected with different types of vacuolar myopathies, namely late onset PD (LOPD), NM, s-IBM, OPMD. Immunohistochemistry for p62, LC3 and/or LAMP2 was compared with routine histological and histochemical staining, in order to evaluate their role as diagnostic tools for the differentiation of autophagic vacuolar myopathies.

**Case selection**

A search of the database of tissue bank at the Neuro muscular Unit was carried out, spanning the interval between 1988 and 2016. Only patients with complete clinical, genetic and follow up data were included.

Twenty patients with a confirmed diagnosis of LOPD (9 men, 11 women; mean age 44.4 ± 28.8); seven sIBM patients (4 men, 3 women; mean age 65 ± 14.9) and four OPMD patients (1 man, 3 women; mean age 55.2 ± 10.1) were included in the study. Moreover, eight patients with NM were also considered (5 men, 3 women; mean age 51.1 ± 21.4). Normal controls (5 men, 5 women; mean age 60.5 ± 7.1) were selected from a larger pool of muscle biopsies characterized by lack of pathologic findings.

Patients characteristics are reported in Table I; levels of plasma creatine kinase prior to biopsy were available in the clinical record in 47 out of 49 subjects. A review of the original muscle biopsy slides was also made.
Table I. Clinical characteristics in 49 cases.

<table>
<thead>
<tr>
<th>Subject ID</th>
<th>Group</th>
<th>CK level (x n.v.)</th>
<th>Sex</th>
<th>Age</th>
<th>Clinical involvement</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>LOPD</td>
<td>3X</td>
<td>F</td>
<td>44</td>
<td>Mild</td>
</tr>
<tr>
<td>2</td>
<td>LOPD</td>
<td>NA</td>
<td>F</td>
<td>34</td>
<td>Absent</td>
</tr>
<tr>
<td>3</td>
<td>LOPD</td>
<td>5X</td>
<td>M</td>
<td>52</td>
<td>Absent</td>
</tr>
<tr>
<td>4</td>
<td>LOPD</td>
<td>8X</td>
<td>M</td>
<td>66</td>
<td>Severe</td>
</tr>
<tr>
<td>5</td>
<td>LOPD</td>
<td>6X</td>
<td>M</td>
<td>34</td>
<td>Mild</td>
</tr>
<tr>
<td>6</td>
<td>LOPD</td>
<td>10X</td>
<td>F</td>
<td>30</td>
<td>Mild</td>
</tr>
<tr>
<td>7</td>
<td>LOPD</td>
<td>2X</td>
<td>F</td>
<td>57</td>
<td>Mild</td>
</tr>
<tr>
<td>8</td>
<td>LOPD</td>
<td>3X</td>
<td>F</td>
<td>74</td>
<td>Severe</td>
</tr>
<tr>
<td>9</td>
<td>LOPD</td>
<td>2X</td>
<td>M</td>
<td>42</td>
<td>Mild</td>
</tr>
<tr>
<td>10</td>
<td>LOPD</td>
<td>4X</td>
<td>F</td>
<td>49</td>
<td>Mild</td>
</tr>
<tr>
<td>11</td>
<td>LOPD</td>
<td>4X</td>
<td>M</td>
<td>1</td>
<td>Absent</td>
</tr>
<tr>
<td>12</td>
<td>LOPD</td>
<td>6X</td>
<td>F</td>
<td>52</td>
<td>Severe</td>
</tr>
<tr>
<td>13</td>
<td>LOPD</td>
<td>2X</td>
<td>M</td>
<td>61</td>
<td>Mild</td>
</tr>
<tr>
<td>14</td>
<td>LOPD</td>
<td>N</td>
<td>M</td>
<td>74</td>
<td>Severe</td>
</tr>
<tr>
<td>15</td>
<td>LOPD</td>
<td>5X</td>
<td>F</td>
<td>39</td>
<td>Absent</td>
</tr>
<tr>
<td>16</td>
<td>LOPD</td>
<td>5X</td>
<td>M</td>
<td>1</td>
<td>Severe</td>
</tr>
<tr>
<td>17</td>
<td>LOPD</td>
<td>4X</td>
<td>F</td>
<td>61</td>
<td>Absent</td>
</tr>
<tr>
<td>18</td>
<td>LOPD</td>
<td>2X</td>
<td>F</td>
<td>49</td>
<td>Absent</td>
</tr>
<tr>
<td>19</td>
<td>LOPD</td>
<td>2X</td>
<td>F</td>
<td>15</td>
<td>Absent</td>
</tr>
<tr>
<td>20</td>
<td>LOPD</td>
<td>N</td>
<td>M</td>
<td>53</td>
<td>Severe</td>
</tr>
<tr>
<td>21</td>
<td>NM</td>
<td>N</td>
<td>F</td>
<td>76</td>
<td>Mild</td>
</tr>
<tr>
<td>22</td>
<td>NM</td>
<td>6X</td>
<td>F</td>
<td>53</td>
<td>Mild</td>
</tr>
<tr>
<td>23</td>
<td>NM</td>
<td>4X</td>
<td>M</td>
<td>29</td>
<td>Severe</td>
</tr>
<tr>
<td>24</td>
<td>NM</td>
<td>N</td>
<td>M</td>
<td>34</td>
<td>Mild</td>
</tr>
<tr>
<td>25</td>
<td>NM</td>
<td>2X</td>
<td>M</td>
<td>82</td>
<td>Mild</td>
</tr>
<tr>
<td>26</td>
<td>NM</td>
<td>38X</td>
<td>M</td>
<td>25</td>
<td>Mild</td>
</tr>
<tr>
<td>27</td>
<td>NM</td>
<td>37X</td>
<td>M</td>
<td>64</td>
<td>Mild</td>
</tr>
<tr>
<td>28</td>
<td>NM</td>
<td>11X</td>
<td>M</td>
<td>46</td>
<td>Mild</td>
</tr>
<tr>
<td>29</td>
<td>IBMyositis</td>
<td>2X</td>
<td>F</td>
<td>33</td>
<td>Severe</td>
</tr>
<tr>
<td>30</td>
<td>IBMyositis</td>
<td>NA</td>
<td>F</td>
<td>61</td>
<td>Mild</td>
</tr>
<tr>
<td>31</td>
<td>IBMyositis</td>
<td>3X</td>
<td>F</td>
<td>71</td>
<td>Severe</td>
</tr>
<tr>
<td>32</td>
<td>IBMyositis</td>
<td>2X</td>
<td>M</td>
<td>68</td>
<td>Severe</td>
</tr>
<tr>
<td>33</td>
<td>IBMyositis</td>
<td>2X</td>
<td>M</td>
<td>77</td>
<td>Mild</td>
</tr>
<tr>
<td>34</td>
<td>IBMyositis</td>
<td>5X</td>
<td>M</td>
<td>73</td>
<td>Mild</td>
</tr>
<tr>
<td>35</td>
<td>IBMyositis</td>
<td>2X</td>
<td>M</td>
<td>72</td>
<td>Severe</td>
</tr>
<tr>
<td>36</td>
<td>OPMD</td>
<td>N</td>
<td>F</td>
<td>59</td>
<td>Mild</td>
</tr>
<tr>
<td>37</td>
<td>OPMD</td>
<td>N</td>
<td>F</td>
<td>66</td>
<td>Severe</td>
</tr>
<tr>
<td>38</td>
<td>OPMD</td>
<td>N</td>
<td>F</td>
<td>42</td>
<td>Mild</td>
</tr>
<tr>
<td>39</td>
<td>OPMD</td>
<td>N</td>
<td>M</td>
<td>54</td>
<td>Mild</td>
</tr>
<tr>
<td>40</td>
<td>CONTROL</td>
<td>N</td>
<td>M</td>
<td>47</td>
<td>Absent</td>
</tr>
<tr>
<td>41</td>
<td>CONTROL</td>
<td>N</td>
<td>M</td>
<td>54</td>
<td>Absent</td>
</tr>
<tr>
<td>42</td>
<td>CONTROL</td>
<td>N</td>
<td>M</td>
<td>58</td>
<td>Absent</td>
</tr>
<tr>
<td>43</td>
<td>CONTROL</td>
<td>N</td>
<td>M</td>
<td>65</td>
<td>Absent</td>
</tr>
<tr>
<td>44</td>
<td>CONTROL</td>
<td>N</td>
<td>M</td>
<td>71</td>
<td>Absent</td>
</tr>
<tr>
<td>45</td>
<td>CONTROL</td>
<td>N</td>
<td>F</td>
<td>62</td>
<td>Absent</td>
</tr>
<tr>
<td>46</td>
<td>CONTROL</td>
<td>N</td>
<td>F</td>
<td>58</td>
<td>Absent</td>
</tr>
<tr>
<td>47</td>
<td>CONTROL</td>
<td>N</td>
<td>F</td>
<td>61</td>
<td>Absent</td>
</tr>
<tr>
<td>48</td>
<td>CONTROL</td>
<td>N</td>
<td>F</td>
<td>59</td>
<td>Absent</td>
</tr>
<tr>
<td>49</td>
<td>CONTROL</td>
<td>N</td>
<td>F</td>
<td>70</td>
<td>Absent</td>
</tr>
</tbody>
</table>
**Muscle biopsy sections**

Serial 7-8 µm sections were cut from muscle samples stored in liquid nitrogen, and parallel processed for hematoxylin and eosin (H&E), modified trichrome Gomori, Periodic acid Schiff (PAS) stain and acid phosphatase stain according with routine procedures.

**Immunohistochemistry**

Immunoperoxidase staining for LC3 (mouse monoclonal antibody, clone 5F10, Nanotools; 1:100 dilution following antigen retrieval) and p62/SQSTM1 (guinea pig polyclonal antibody, Progen Biotechnik; 1:100 dilution following antigen retrieval) was performed on frozen tissue samples.

For LAMP2 we used purified rat anti-mouse CD107b monoclonal antibody, clone ABL-93, BD Biosciences, 1:100).

**Quantification**

Quantification was performed on muscle sections using a bright-field light microscope, with the investigator blind to group assignment of each subject. Prior to counting, each slide was viewed at low (2x-20x) and high power (40x) to determine whether positive fibers were present scarcely or in abundance. Muscle fibers containing the characteristic central inclusion, rimmed vacuoles, or punctate staining pattern were counted as positive, while fibers devoid of staining were counted as negative. The same criteria were used for morphological and histochemical stainings. A total of 200 fibers/slide were counted in specimens with abundant positivity, while a total of 600 fibers/slide was counted in specimens with scarce or patchy positivity (to reduce the sampling error). Tissue on the slide was divided into quadrants and randomly selected, non-overlapping fields were counted at high power in each quadrant until the total count was reached. The results were recorded as a percentage (the number of positive fibers divided by the total number of fibers counted).

**Imaging**

Images were taken with an AXIO digital camera on a BX41 bright-field light microscope using cellSens Entry 1.4 software (all by Olympus Corp) and were edited with Adobe Photoshop Version 12.0.2.

**Statistical methods**

Data were analyzed with SPSS statistical software (Version 18). For between-group comparison of the demographic data we used one-way ANOVA with post-hoc Bonferroni test (age and sex). To calculate sensitivity and specificity receiver operating characteristic (ROC) analysis was performed on all muscle biopsies. All tests were 2-tailed with \( \alpha = 0.05 \).

**Results**

Detailed results of the percentage of positive fibers for each staining are reported in Table II. On light microscopy, we identified several histologic patterns suggestive of different categories of vacuolar myopathies.

In the LOPD patients group, characterized by variable clinical and muscle tissue involvement, LAMP2 and LC3 were positive in 65% of patients, whereas p62 positivity was seen only in 25% of subjects with a finely punctate staining pattern, paralleling morphological, PAS and acid phosphatase reactions (55%) (Fig. 1A, 2). No correlation with the clinical features was observed.

The NM group presented more extensive alterations with all methods, showing variable and heterogeneous expression of LAMP2 (7 out of 8 cases) and LC3 in 4 subject (Fig. 3), mainly in necrotic fibers, with less specificity; interestingly, p62 positivity was strongly observed only in 2 cases (22 and 27), both of them with a necrotizing myopathy of unknown origin and severe rhabdomyolysis.

In IBM group, p62 and LC3 were diffusely expressed; in particular, p62 was positive in all eight subjects (Fig. 4B) respect to LC3 positivity in 6 cases (Fig. 4D). Differently from the NM group, LAMP2 showed a less significant expression in 6 cases (Fig. 4C).

In OPMD group, p62, LAMP2 and LC-3 were substantially negative in all cases, with LC3 mild unspecific staining only in a couple of fibers in 2 patients, LAMP2 in 1 case and no positivity for p62 antibody in all cases (data non shown).

In normal control sample, there was no intrafibral staining (Fig. 5B, C and D); a typical normal nuclear positivity was seen on LC3, LAMP2 and p62-stained sections.

There was no statistically significant difference in the mean age among the five groups (LOPD 44.4 ± 20.83 vs VM 51.1 ±21.49 vs IBM 65 ± 14.95 vs OPMD 55.2 ± 10.11 vs CONTROLS 60.5 ± 7.16 years; \( p = 0.056 \)) or sex distribution (LOPD 55% vs VM 25% vs IBM 43% vs OPMD 75% vs CONTROLS 50% female, respectively; \( p = 0.019 \)).

Figures 6 to 8 show the percentage of LC-3, LAMP2 and p62 positive fibers respectively in the different patients groups compared with the control group.

As expected, the higher percentage of positive fibers for autophagy markers is observed in LOPD patients, with a major occurrence of LAMP2 and LC3 staining;
however, also in NM and in sIBM these three antibodies seem to have a different significance recognizing different patterns. In fact, whereas the percentage of LC3 and LAMP2 positive fibers is not statistically significant between different groups (Figs. 6, 7), the percentage of p62-positive fibers in muscle sections was significantly higher in sIBM group than in LOPD (p < 0.001 ANOVA with Bonferroni correction), OPMD (p < 0.01 ANOVA with Bonferroni correction) and in the control group (p < 0.001 ANOVA with Bonferroni correction) (Fig. 8); p62 positivity was also observed in muscle fibers showing normal histochemical features. ROC analysis of our data indicates a 100% specificity and 75% sensitivity of p62 staining for IBM.

Table II. Percentage of positive fibers for morphological, histochemical and immunohistochemical staining in 39 patients. All controls were completely negative.

<table>
<thead>
<tr>
<th>Subject ID</th>
<th>Group</th>
<th>LC-3 (% positive fibers)</th>
<th>p62 (% positive fibers)</th>
<th>LAMP2 (% positive fibers)</th>
<th>HE (% vacuolated fibers)</th>
<th>TRIC (% vacuolated fibers)</th>
<th>PAS (% vacuolated positive fiber)</th>
<th>Acid phosphatase (% positive fibers)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>LOPD</td>
<td>3.5</td>
<td>4</td>
<td>6.5</td>
<td>3</td>
<td>13.5</td>
<td>5.5</td>
<td>3</td>
</tr>
<tr>
<td>2</td>
<td>LOPD</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>3</td>
<td>LOPD</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>4</td>
<td>LOPD</td>
<td>37.5</td>
<td>2</td>
<td>25</td>
<td>25</td>
<td>45</td>
<td>45</td>
<td>20</td>
</tr>
<tr>
<td>5</td>
<td>LOPD</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>6</td>
<td>LOPD</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>7</td>
<td>LOPD</td>
<td>6</td>
<td>0</td>
<td>1.5</td>
<td>3</td>
<td>23.5</td>
<td>4</td>
<td>3</td>
</tr>
<tr>
<td>8</td>
<td>LOPD</td>
<td>7.5</td>
<td>4.5</td>
<td>14</td>
<td>7.5</td>
<td>13</td>
<td>5</td>
<td>2</td>
</tr>
<tr>
<td>9</td>
<td>LOPD</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1.5</td>
<td>0</td>
<td>0</td>
<td>1.5</td>
</tr>
<tr>
<td>10</td>
<td>LOPD</td>
<td>0.5</td>
<td>0</td>
<td>3.5</td>
<td>2</td>
<td>1.5</td>
<td>1.5</td>
<td>3</td>
</tr>
<tr>
<td>11</td>
<td>LOPD</td>
<td>0</td>
<td>0</td>
<td>14</td>
<td>5</td>
<td>4.5</td>
<td>8.5</td>
<td>2.5</td>
</tr>
<tr>
<td>12</td>
<td>LOPD</td>
<td>12.5</td>
<td>4</td>
<td>26</td>
<td>12.5</td>
<td>10</td>
<td>20</td>
<td>7.5</td>
</tr>
<tr>
<td>13</td>
<td>LOPD</td>
<td>28</td>
<td>0</td>
<td>34</td>
<td>26.25</td>
<td>40</td>
<td>25</td>
<td>7.5</td>
</tr>
<tr>
<td>14</td>
<td>LOPD</td>
<td>8.5</td>
<td>0</td>
<td>10</td>
<td>6</td>
<td>3.5</td>
<td>3.5</td>
<td>3</td>
</tr>
<tr>
<td>15</td>
<td>LOPD</td>
<td>21.5</td>
<td>2</td>
<td>25.5</td>
<td>20</td>
<td>15</td>
<td>18.5</td>
<td>15</td>
</tr>
<tr>
<td>16</td>
<td>LOPD</td>
<td>6</td>
<td>0</td>
<td>0</td>
<td>75</td>
<td>75</td>
<td>75</td>
<td>75</td>
</tr>
<tr>
<td>17</td>
<td>LOPD</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>18</td>
<td>LOPD</td>
<td>16</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>19</td>
<td>LOPD</td>
<td>0</td>
<td>0</td>
<td>0.5</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>20</td>
<td>LOPD</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>21</td>
<td>NM</td>
<td>2.5</td>
<td>0</td>
<td>7</td>
<td>15</td>
<td>10</td>
<td>5</td>
<td>2.5</td>
</tr>
<tr>
<td>22</td>
<td>NM</td>
<td>0</td>
<td>21</td>
<td>1</td>
<td>0.5</td>
<td>1</td>
<td>1</td>
<td>2.5</td>
</tr>
<tr>
<td>23</td>
<td>NM</td>
<td>1</td>
<td>0</td>
<td>1.5</td>
<td>1.5</td>
<td>0</td>
<td>3</td>
<td>0</td>
</tr>
<tr>
<td>24</td>
<td>NM</td>
<td>0</td>
<td>0</td>
<td>1.5</td>
<td>10</td>
<td>7.5</td>
<td>10</td>
<td>3</td>
</tr>
<tr>
<td>25</td>
<td>NM</td>
<td>2</td>
<td>1</td>
<td>2.5</td>
<td>2.5</td>
<td>1</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>26</td>
<td>NM</td>
<td>0</td>
<td>0</td>
<td>9</td>
<td>0.5</td>
<td>0.5</td>
<td>0</td>
<td>12.5</td>
</tr>
<tr>
<td>27</td>
<td>NM</td>
<td>19</td>
<td>13</td>
<td>14</td>
<td>4.5</td>
<td>5</td>
<td>2</td>
<td>6.5</td>
</tr>
<tr>
<td>28</td>
<td>NM</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>0.5</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>29</td>
<td>sIBM</td>
<td>9</td>
<td>6</td>
<td>15</td>
<td>18.5</td>
<td>25</td>
<td>1.5</td>
<td>2</td>
</tr>
<tr>
<td>30</td>
<td>sIBM</td>
<td>9</td>
<td>5.5</td>
<td>6.5</td>
<td>6</td>
<td>6</td>
<td>0</td>
<td>1.5</td>
</tr>
<tr>
<td>31</td>
<td>sIBM</td>
<td>9.5</td>
<td>7</td>
<td>2.5</td>
<td>5</td>
<td>7.5</td>
<td>1.5</td>
<td>1.5</td>
</tr>
<tr>
<td>32</td>
<td>sIBM</td>
<td>5.5</td>
<td>15.5</td>
<td>3.5</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>33</td>
<td>sIBM</td>
<td>8</td>
<td>5.5</td>
<td>4.5</td>
<td>6</td>
<td>3.5</td>
<td>0</td>
<td>1.5</td>
</tr>
<tr>
<td>34</td>
<td>sIBM</td>
<td>0</td>
<td>14.5</td>
<td>2.5</td>
<td>1.5</td>
<td>0</td>
<td>0</td>
<td>0.5</td>
</tr>
<tr>
<td>35</td>
<td>sIBM</td>
<td>6</td>
<td>5.5</td>
<td>0</td>
<td>2.5</td>
<td>1.5</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>36</td>
<td>OPMD</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>37</td>
<td>OPMD</td>
<td>1.5</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>38</td>
<td>OPMD</td>
<td>1.5</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>39</td>
<td>OPMD</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>2</td>
<td>1.5</td>
<td>0</td>
<td>0.5</td>
</tr>
</tbody>
</table>
Differential diagnosis of vacuolar myopathies is usually achieved with the routine set of histological and histochemical staining on frozen muscle tissue; congruent clinical data are also necessary to distinguish among the great variety of myopathological entities. In some outlier cases, with only minor changes and with partial or incomplete clinical data, the ultrastructural exam may be necessary to reach a definitive diagnosis. However, this procedure is not diffusely available, is expensive and time-consuming.

In this study, we evaluated only by immunohistochemistry the potential adjunctive utility of p62, LC3 and LAMP2 in four groups of muscle disorders characterized by intrafibril vacuoles, and in a group of normal controls.

In LOPD, a lysosomal disease with defective autophagy, LC3, LAMP2 and p62 stainings were comparably positive with a punctate pattern, reflecting the association of LC3-II with the membranes of early autophagosomes, whereas p62 puncta correspond to the accumulation of protein aggregates within early autophagic (LC3-positive) vesicles; hence, the increased punctate staining seen with these markers corresponds to autophagosome...
Differential diagnosis of vacuolar muscle biopsies: use of p62, LC3 and Lamp2 immunohistochemistry

The observed minor incidence of p62 fibers in LOPD group may reflect the different stages of the autophagic process in these patients. In LOPD, LC3 seems to have the higher sensibility, in comparison to conventional stainings and the other markers. However, no LOPD case was detected by immunohistochemistry alone associated to a negative histochemical staining. In fact, in six out of 20 LOPD cases (30%), quadriceps muscle biopsy was totally normal, confirming the need to perform the biochemical test in all cases with a clinical suspect.

In most cases of clinically defined sIBM, intrafibrilar vacuoles show the typical ‘red rim’ staining with Gomori’s trichrome and are easily recognized. However, non-rimmed vacuoles are also observed, and a possible activation of autophagic pathway is also hypothesized (18). Immunohistochemistry in sIBM biopsies is often characterized by aspecific and variable staining by a variety of antibodies utilized in the routine muscle biopsy diagnostic study, making this procedure less significant in sIBM diagnosis. In all sIBM cases of our study, we found a significant positivity only for p62, with small positive puncta distributed throughout the sarcoplasm of a higher number of fibers in comparison to the other markers, supporting the hypothesis of a specific autophagic activation in these cases. (Fig. 4B, C and D). In LOPD cases, the puncta were larger and primarily (although not exclusively) located in the center of a reduced number of fibers. Several earlier studies have examined LC3, p62 or LAMP2 staining in the setting of IBM; however, no single work quantitatively compared all three markers on the same set of well-defined specimens (19). In our study p62, but not LC3 and LAMP2, effectively distinguished buildup (17).
the sIBM subject group from other vacuolar myopathy subject; moreover, p62 immunohistochemistry showed the best tradeoff between sensitivity and specificity for sIBM as a diagnostic test applied to an individual case. The p62 staining was qualitatively similar to LC3 staining, consistent with the idea that accumulation of either LC3-labeled autophagosomes or p62-positive aggregates are a marker of autophagic flux inhibition in sIBM.

In OPDM, also characterized by the presence of intrafibrilar vacuoles, the presence of autophagic activation was excluded in all cases; therefore immunohistochemistry may be useful in the differential diagnosis when clinical data are lacking or unsupportive, in particular in the presence of rimmed vacuoles.

Immunohistochemistry for autophagic markers did not add any additional information in necrotizing myopathies, since necrotic fibers showed a variable and unspecific staining with all antibodies. Interestingly, two patients presented a strong autophagic activation, thus challenging the diagnosis, and a specific follow up is ongoing.

Based on these findings, we can conclude that p62, LAMP2 and LC3 immunohistochemistry have a significant role in the routine study of muscle when clinical data are not supportive, and could be included in the panel of antibodies when a vacuolar myopathy is observed with histological procedure. In particular, LC3 antibodies have a slightly higher specificity in LOPD biopsies, whereas a strong selective p62 positivity seem to be more indicative of sIBM. On the contrary, LAMP2 does not add important clues in differential diagnosis of these pathologies.

References

Study of anti-Müllerian hormone levels in patients with Myotonic Dystrophy Type 1. Preliminary results

Manuela Ergoli*, Massimo Venditti*, Raffaele Dotolo*, Esther Picillo1, Sergio Minucci2 and Luisa Politano1

1 Cardiomyology and Medical Genetics and 2 Section of Biology, Department of Experimental Medicine, University of Campania “Luigi Vanvitelli”, Naples, Italy

Study of anti-Müllerian hormone levels in patients with Myotonic Dystrophy Type 1. Preliminary results

Manuela Ergoli1*, Massimo Venditti2*, Raffaele Dotolo2*, Esther Picillo1, Sergio Minucci2 and Luisa Politano1

1 Cardiomyology and Medical Genetics and 2 Section of Biology, Department of Experimental Medicine, University of Campania “Luigi Vanvitelli”, Naples, Italy

Myotonic dystrophy type 1 is a multisystemic disorder characterized by myotonia, muscle weakness and involvement of several organs and apparatus such as heart, lungs, eye, brain and endocrine system. Hypogonadism and reproductive abnormalities are frequently reported. A progressive testicular atrophy occurs in about 80% in the affected males leading to Leydig cell hyperproliferation and elevated basal follicle stimulating hormone (FSH) levels. Anti-Müllerian hormone (AMH) – a dimeric glycoprotein belonging to the super-family of transforming grow factor beta (TGF-beta) – is the earliest Sertoli cell hormone secreted in males and, together with inhibin B and FSH, is an important indicator of Sertoli cell function. AMH levels remain high during the whole prepubertal phase and are down-regulated in puberty by the increasing testosterone levels. Aims of the work were to assess the AMH levels in 50 patients with Myotonic Dystrophy type 1 aged less 50 years and to investigate whether it may contribute to the endocrine function impairment observed in these patients. The results confirmed a reduction of testosterone levels associated with an increase in Luteinizing Hormone (LH) and FSH compared to controls, suggesting a reduced function of the Sertoli cells. Conversely the average levels of AMH were significantly lower in patients compared with controls, and almost undetectable in about 60% of them. Further studies are necessary to better clarify these findings.

Key-words: myotonic dystrophy type 1, gonadal function, anti-Müllerian hormone

Introduction

Myotonic dystrophy type 1 (DM1) or Steinert disease is a multisystemic disorder characterized by myotonia, muscle and facial weakness, cataract, cognitive and gastrointestinal involvement, and cardiac conduction abnormalities (1). DM1 is the most common adult muscular dystrophy with a global incidence of 1:8000. Symptoms appear between 20 and 40 years of age and the localization of muscle weakness is predominantly distal (1-4). It is a RNA-mediated disease caused by a trinucleotide expansion, the CTG repeat in the DMPK gene (4) on the long arm of chromosome 19 (19q13-2). The endocrine system is also frequently involved as hypogonadism and reproductive abnormalities (1-4). Progressive testicular atrophy is a prominent feature and occurs with an incidence of 80% in the affected males (5). The observed histological abnormalities include tubular atrophy, hyalinization and fibrosis of seminiferous tubules as far as a reduced sperm number. Oligo/azoo-spermia is reported in 73% of DM1 patients while low serum testosterone levels are observed in most patients. The progression of the disease leads to Leydig cell hyperproliferation, elevated basal follicle stimulating hormone (FSH) levels and gonadal dysfunction (6-13). Therefore the evaluation of gonadal function, including interstitial Leydig cells and tubular Sertoli cell hormone production, is recommended in the workup of male hypogonadism.

Anti-Müllerian hormone (AMH) is a dimeric glycoprotein composed of two 72 KDa monomers belonging to the super-family of transforming grow factor beta (TGF-beta) (14). The coding gene for this hormone is localized in humans on the short arm of chromosome 19.

* These Authors contributed equally to the work.

Address for correspondence: Luisa Politano, Cardiomiologia e Genetica Medica, I Policlinico, piazza Miraglia, 80138 Napoli, Italy. E-mail: luisa.politano@unicampania.it

199
Manuela Ergoli et al.

(19p13.3). The gene spans 275 bp and is subdivided into five exons. The expression of AMH in males is usually restricted to foetal and post-natal testosterone cells, and, in females, in post-natal granulosa cells.

The AMH molecule takes its name from the first function described in foetal sex differentiation, the regression of Müller ducts in the early phase of male differentiation. In the male foetus the Sertoli cells secrete AMH and androgens. Androgens in turn stimulate the evolution of Wolff’s ducts into the male genital apparatus, while AMH causes the irreversible regression of the Müller’s ducts, which is completed at the end of the ninth week of gestation. With the exception of a transient decrease in the perinatal period, the testicular secretion of AMH remains at high levels until puberty (Fig. 1) (14-16). For such behaviour, AMH dosage was proposed as a marker for the evaluation of Sertoli cell activity and an early identification of the pre-puberal male hypogonadism (17-23).

The study aimed at evaluating the gonadal function of patients with Myotonic Dystrophy type 1, and the possible involvement of the AMH in mechanisms underlying the hypogonadism and reproductive abnormalities frequently observed in these patients. The purpose was to highlight a possible association between testosterone, LH, FSH and estradiol levels with those of AMH, and to investigate a possible correlation between AMH levels and age of patients and/or degree of CTG triplet expansion.

Subjects and methods

Fifty male patients affected by Myotonic Dystrophy type 1 aged between 18 and 50 years, regularly followed at the Cardiomyology and Medical Genetics of the “L. Vanvitelli” University, and 60 age-matched adult males were consecutively enrolled in the study.

All patients had the clinical diagnosis confirmed by molecular analysis to define the magnitude of the triplet expansion. In practice, on the occasion of the routine follow up, a blood sample was taken for hormone (testosterone, 17β-estradiol, luteinizing and stimulating follicle hormones) dosage, while an aliquot of the collected serum was used to dose the AMH. A written informed consent was obtained from all participants to the study, that was approved by the local ethical committee.

The hormone dosage was performed according to CLIA Method DiaSorin, while AMH was dosed by a II generation ELISA kit (Beckman Coulter, Brea, CA, USA).

Statistical analysis

The values are shown as mean ± SEM. Statistical differences were analysed by Student t test for non paired data; significance was put for p values < 0.05.

Results

The results are summarized in Table I and Figure 2.

Serum testosterone levels – although within the normal ranges – were on average significantly lower in DM1 than in controls (272.4 ± 55.8 ng/dL vs 563.3 ± 80.74 ng/dL, p value 0.0083; Fig. 2A).

The average values of LH and FSH were above the maximum limit of normality and statistically higher than in controls (11.1 ± 2.9 UI/L vs 4.4 ± 0.8 UI/L, p value < 0.0425, and 19.4 ± 4.7 UI/L vs 6.0 ± 1.4 UI/L, p value < 0.013, respectively; Fig. 2B-C).

Conversely, the average values of estradiol were not significantly different compared to controls (27.2 ± 3.7 pg/ml vs 30.5 ± 5.0 pg/ml, p value 0.6; Fig. 2D).

Focusing on AMH levels, a broad spectrum of values was observed in patients with DM1, ranging from 0.01 to 8.5 ng/ml. Furthermore 59% of them showed almost undetectable values (0.11 ± 0.07 ng/ml, p value 0.0064).

The mean value of the whole group was 2.4 ± 1.4 ng/ml, significantly lower compared with controls (6.4 ± 1.4 ng/ml, p value 0.0318; Fig. 2E).

To be noted that patients who had almost undetectable values of AMH, presented also the highest values of LH and FSH (14.4 ± 4.3 UI/L vs 3.7 ± 0.95 ng/ml and 24.9 ± 5.6 vs 5.3 ± 1.3 UI/L), and the differences were statistically significant (p value 0.042, 0.006 and 0.006 respectively; Fig. 2F).

A trend to a negative correlation between AMH levels and age of patients and size of triplet expansion were observed (see Figures 3A and 3B, respectively).
Discussion

Myotonic Dystrophy type 1 is a multisystem disease, with a wide pattern of clinical manifestations. Among these, the alterations of the endocrine system and in particular hypogonadism is one of the most frequently observed feature. The evaluation of the gonadal function, including interstitial Leydig cells and tubular Sertoli cells hormone production, is therefore recommended in these patients by the routine investigation of serum levels of testosterone, LH, FSH, and estradiol. As AMH has recently shown to play an important role in development of gonads and testicular function, and indicated as a possible marker of spermatogenesis, the dosage of serum AMH levels is also recommended. The evaluation of the gonadal function confirmed a condition of hypogonadism in our population, as serum testosterone levels were significantly lower compared to controls tough within the normal ranges. “However an impairment of the endocrine function and in particular of the Sertoli cells can be hypothesized by the observation that LH and FSH mean levels are statistically higher compared with controls.

Interestingly, it was observed that the average levels of AMH were significantly lower in patients compared with controls, and almost undetectable in about 60% of them. A trend to an inverse correlation between AMH and FSH levels was observed as the lower AMH levels were, the higher the levels of FSH. Further investigation are necessary to better define the contribution of the AMH in the impairment of the endocrine function in these patients, as far as that of proteins recently shown to be implicated in spermatogenesis (25-28).

References

The multifaceted clinical presentation of VCP-proteinopathy in a Greek family

GEORGE K. PAPADIMAS1, GEORGE P. PARASKEVAS1, THOMAS ZAMBELIS1, CHRISOSTOMOS KARAGIAOURIS1, MARA BOURBOULI1, ANASTASIA BOUGEA1, MAGGIE C. VOLTER2, NICOLAS U. SCHUMACHER2, SABINE KRAUSE2 AND ELISABETH KAPAKI1

1 1st Department of Neurology, Eginition Hospital, Medical School, National and Kapodistrian University of Athens, Greece; 2 Friedrich-Baur-Institute, Department of Neurology, Ludwig-Maximilians University, Munich, Germany

VCP-proteinopathy is a multisystem neurodegenerative disorder caused by mutations in valosin containing protein. Here, we report the first Greek case of VCP-proteinopathy in a 62 year old patient with a slowly progressing muscular weakness since his mid-40s and a severe deterioration during the last year. He also manifested dementia with prominent neuropsychiatric symptoms, including aggression, apathy, palilalia and obsessions. Brain MRI revealed frontal atrophy, while muscle MRI showed diffuse muscle atrophy. Family history was positive and several members of the family had been diagnosed with motor neuron disease, dementia or behavioral symptoms. Sequencing of the VCP gene revealed a pathogenic heterozygous missense mutation p.R159H. Conclusively, the present report highlights the intrafamilial variability and broadens the phenotypic spectrum of VCP-proteinopathy.

Key words: VCP, ALS, dementia

Introduction

Valosin Containing Protein (VCP) mutations have been well recognized as a cause of dominantly inherited Inclusion Body Myopathy, Paget’s Disease and Frontotemporal Dementia (IBMPFD), although the term multisystemic proteinopathy has been proposed as a prevailing nomenclature in order to also include non-VCP IBMPFD and other rarer phenotypes, such as parkinsonism and peripheral neuropathy (1). IBMPFD (OMIM 167320) was firstly described in 2000 by Kimonis et al. (2) and the disease locus (VCP gene; 601023) was mapped to chromosome 9p13.3-p12 (3). VCP belongs to the cytosolic chaperone AAA class of ATPases of the endoplasmic reticulum-associated degradation (ERAD) system and is involved in many different cellular functions and signaling pathways, with its most important role facilitating proteasome-mediated degradation of misfolded polypeptides (4).

The clinical picture of the disease, as implied by its acronym, includes myopathy, Paget’s disease and frontotemporal dementia with incomplete penetrance. Myopathy is the most common manifestation (~90%) and muscle weakness of variable pattern, either proximal or distal, may be usually the presenting symptom with onset in 3rd to 4th decade. Bone involvement is observed in almost half of the patients, while dementia of the frontotemporal type is a later onset symptom affecting approximately a third of the patients. However, the phenotypic spectrum of the disease has now broadened to include less frequent manifestations such as motor neuron disease, parkinsonism and Charcot-Marie-Tooth - like disease (1).

Herein, we describe the first Greek case of myopathy combined with an early onset progressive cognitive decline in a patient with a VCP mutation and a positive family history of neurodegenerative disorders, such as dementia and ALS.

Case report

The index patient is a 62 year old male with a personal history of arterial hypertension and an operation for herniated disc at the L4-L5 level at the age of 48 years. The symptoms began approximately in his mid-forties with steppage gait. His walking difficulties progressively worsened, especially during the last year and at the time of admission, he was no longer able to walk without aid. He also developed neuropsychiatric symptoms and in
particular episodes of aggression and obsessions treated with atypical neuroleptics, such as quetiapine, with a satisfactory response, while he thereafter developed palilalia and apathy which still persist.

His mother had been diagnosed with “presenile dementia” and died at the age of 63 y (Fig. 1). His older brother had been diagnosed in his forties with classical ALS with a combination of upper and lower motor neuron involvement and subsequently died at 53 y. Another brother has been reported with behavioral symptoms since the age of 55 y.

On examination, the patient was unable to stand and walk without bilateral assistance. Although strength assessment of individual muscles was quite difficult due to poor cooperation, there was a severe symmetrical muscular weakness and a diffuse wasting in all muscles of upper and lower extremities, particularly prominent distally in lower limbs. Deep tendon reflexes were traced in upper and lower extremities, while no pathologic reflexes were elicited. Neuropsychological evaluation was abnormal with impaired conceptualization, mental flexibility and motor programming.

Laboratory studies, including serum creatine phosphokinase (CPK), transaminases (AST, ALT) and alkaline phosphates (ALP) were normal. Brain MRI revealed frontal lobe atrophy (Fig. 2). Bone radiographs did not reveal any abnormality suggestive of Paget’s disease. Nerve conduction studies showed slightly low amplitudes of peroneal and tibial nerves obviously due to significant axonal loss, while EMG showed diffuse myopathic changes and mild spontaneous activity in the form of fibrillations and positive sharp waves in distal leg muscles. Muscle biopsy of the left vastus lateralis was not informative as it showed severe and non specific end stage changes with fibroadipose tissue replacement. Muscle MRI of lower limbs showed extended atrophy and fatty degeneration in almost all lower leg muscles with a relative sparing of the left biceps femoris at thigh level (Fig. 3), while muscle MRI of upper limbs revealed diffuse atrophy and fibroadipose tissue replacement especially of the posterior compartment.

![Figure 1](image1.png)

**Figure 1.** Pedigree of the patient’s family (arrow indicates the index patient). Main symptoms and present age or age at death are indicated.

![Figure 2](image2.png)

**Figure 2.** T1 weighted brain magnetic resonance image (MRI) transverse image showing frontal lobe atrophy (arrow).

![Figure 3](image3.png)

**Figure 3.** Muscle MRI of thigh and lower legs showing extensive T1w hyperintensity in most muscle groups suggesting severe fatty and/or fibrous degeneration. At thigh level there is an asymmetric relative sparing of the left biceps femoris and to a lesser extent of the left gracilis with a severe involvement of the other muscles and a characteristic patchy appearance particularly in vastus lateralis. At lower leg level there is also a severe involvement of both anterior and posterior compartment with a patchy appearance of anterior tibialis and peroneal muscles and a relative sparing of tibialis posterior muscle.
and anterior compartment of the arm (more pronounced in biceps and triceps) and to a lesser extent of the forearm muscles. Diagnosis of IBMPFD was confirmed by direct Sanger sequencing of coding regions and flanking intronic regions in the VCP gene, which revealed a heterozygous missense mutation p.R159H (c.476G>A).

**Discussion**

IBMPFD is a rare, clinically heterogeneous disorder transmitted in an autosomal dominant manner (1). Myopathy is by far considered as the prevailing presenting symptom in most cohorts, though with variable pattern of muscle involvement. Although proximal shoulder and pelvic muscle weakness is frequently observed, a scapulopeloneal or a predominant distal phenotype has also been reported, even at the onset of the disease (5-7). A selective pattern of muscle involvement mainly affecting glutei, hamstrings and calf muscles, may be observed on muscle MRI, usually with an inhomogeneous distribution of fatty replacement (8). Early-onset dementia of frontotemporal type may occur in approximately one third of patients, diagnosed at a mean age of 55 years (1). Quite interestingly, cognitive decline and behavioral changes are observed in most affected members of the present family and indeed the mother of the index patient has suffered from a pure dementing syndrome, although some degree of a concomitant myopathy cannot be definitely excluded.

In the present case, the family history with the constellation of symptoms, such as myopathy, dementia and an ALS-like syndrome in members of consecutive generations, which are indicative of an apparently autosomal dominant inheritance pattern, raised the suspicion for a possible VCP-associated syndrome. Sequencing analysis of the VCP gene in the index patient revealed the already known p.R159H pathogenic mutation. This mutation has been previously described in few families with a heterogeneous presentation and severity of disease. More specifically some affected members have been diagnosed with familial ALS (fALS) and/or FTD without signs of myopathy, whereas another family had affected members with a milder phenotype consisting of myopathy and PD without signs of dementia despite their age being far above the mean age at onset of FTD in VCP carriers (9, 10). Since an increasing body of evidence suggests that ALS may be part of a wide clinical spectrum, targeted genetic panel testing may be considered in familial cases of co-occurrence of ALS with dementia syndrome and/or myopathy including VCP, C9orf72, TARDBP, SQSTM1, MATR3, HNRNPA2B1, and CHCHD10 (11).

Currently, more than 20 genes were identified to cause ALS and FTD. On the genetic basis, the complex network that underlies the pathogenesis of ALS and FTD was elucidated. Interestingly, disease-related mutant proteins form aberrant aggregates in two essential cellular machineries: The RNA quality and protein quality control machineries. Aggregations are hallmarks of many neurodegenerative disorders, and inclusions of the ubiquitous, highly conserved RNA binding protein TDP-43 represent the most important unifying marker throughout ALS molecular pathology. VCP/p97 is an important TDP-43 interaction partner and VCP proteinopathy contributes to TDP-43 dysregulation. Furthermore, TDP-43 proteinopathy is also predominantly associated with a certain frontotemporal lobar dementia (FTLD) subtype Ub+(FTLD-U)/TDP+ (FTLD-TDP). Therefore, ALS and the FTLD-TDP subtype are thought to represent different clinical manifestations of a common pathological pathway (12). Notably, aggregated, cytoplasmic TDP-43 inclusions have been detected in both hereditary and sporadic ALS with or without TARDPB mutations. Toxic gain of function and loss of function mechanisms for TDP-43 are discussed. Furthermore, at least three ALS-related genes, including VCP, MATR3 and SQSTM1/p62, have been implicated in distal myopathies (11). The evidence of combined ALS/distal myopathy phenotypes in some individuals and the presence of TDP-43 inclusions on muscle biopsy further support the hypothesis of an ALS-FTLD/myopathy continuum.

Conclusively, the present case adds to the phenotypic heterogeneity in VCP proteinopathy and highlights an even striking intrafamilial variation. Myopathy followed by rapidly cognitive decline was the clinical presentation of the index case, while the other siblings presented with different phenotypes, such as dementia and ALS. Overall, the poor genotype-phenotype correlation possibly implies that other modifying factors may contribute to the clinical heterogeneity of VCP mutations. The elucidation of the underlying pathomechanisms may explain the clinical diversity and will be essential in providing relatively accurate prognostic information and genetic counseling.

**References**


Three new cases of dilated cardiomyopathy caused by mutations in LMNA gene

LARYSA N. SIVITSKAYA¹, NINA G. DANILENKO¹, TATIYANA G. VAIKHANSKAYA², TATSIYANA V. KURUSHKA² AND OLEG G. DAVYDENKO¹

¹ Institute of Genetics and Cytology, National Academy of Sciences of Belarus, Minsk, Belarus; ² Republican Scientific and Practical Center of Cardiology, Minsk, Belarus

Three cases of dilated cardiomyopathy (DCM) with conduction defects (OMIM 115200), limb girdle muscular dystrophy 1B (OMIM 159001) and autosomal dominant Emery-Dreifuss muscular dystrophy 2 (OMIM 181350), all associated with different LMNA mutations are presented. Three heterozygous missense mutations were identified in unrelated patients – p.W520R (c.1558T > C), p.T528R (c.1583C > G) and p.R190P (c.569G > C). We consider these variants as pathogenic, leading to isolated DCM with conduction defects or syndromic DCM forms with limb-girdle muscular dystrophy and Emery-Dreifuss muscular dystrophy. The mutations were not detected in the ethnically matched control group and publicly available population databases. Their de novo occurrence led to the development of the disease that was not previously detected in the extended families. Mutations at the same codons associated with laminopathies have been already reported. Differences in the clinical phenotype for p.R190P and p.T528R carrier patients are shown and compared to previous reports.

Key words: dilated cardiomyopathy, limb-girdle muscular dystrophy, Emery-Dreifuss muscular dystrophy

Background

The LMNA gene (1q21-22, MIM 150330) encodes two proteins of the nuclear envelope – lamin A and C. They are intermediate filament proteins necessary for functioning and structural integrity of the nucleus. Lamins consist of an amino-terminal head domain, a coiled-coil central rod domain and a carboxy-terminal tail domain (Fig. 1A). They form dimers by rod domains and then associate in head-to-tail polymers creating complex network conjunction with other proteins located underneath the inner membrane of the nucleus. Mutations in LMNA affect lamins’ dimerization and assembly (1, 2). It apparently leads to nuclear stability loss and inability to perform functions in its entirety. The mutations in LMNA lead to at least 10 clinically distinct phenotypes, termed laminopathies, affecting different tissues including cardiac and skeletal muscle, cutaneous, nervous and adipose tissue. There is no explicit relation between syndrome development and mutation domain localization. A number of hot spots were described in LMNA, but the mutations common for laminopathies were not found. Matching definite laminopathy symptoms with LMNA mutations brings us closer to understanding the genetic basis of the disease. Linkage analyses in affected families allow for prognosis and medication steps for mutation carriers.

This report presents three cases of laminopathy: dilatation cardiomyopathy with conduction defects (DCM, OMIM 115200), limb girdle muscular dystrophy 1B (LGMD, OMIM 159001) and autosomal-dominant Emery-Dreifuss muscular dystrophy 2 (EDMD, OMIM 181350) associated with the different LMNA mutations.

Methods

Patients and controls

Patients with DCM and conduction defects from the Scientific and Practical Center of Cardiology (Minsk, Belarus) were referred to Institute of Genetics and Cytology (Minsk, Belarus) for mutation analysis of the LMNA gene. The clinical diagnoses of patients included isolated DCM with conduction defects and syndromic DCM forms with limb-girdle muscular dystrophy and Emery-Dreifuss...
muscular dystrophy. Clinical syndromes were diagnosed according to the currently established criteria (3-5).

The control group consisted of 315 ethnically matched individuals without cardiovascular diseases, physical and neurological abnormalities, a family history of DCM or sudden cardiac death. They were selected from a previously studied population cohort (6).

Informed consent was obtained from all participants. Clinical surveillance and genetic investigation were performed in accordance with the recommendations of the local ethics committee of the Belarusian State Medical University and the Scientific Board of the Institute of Genetics and Cytology of the National Academy of Sciences, Belarus.

**Genetic analysis**

Genomic DNA was obtained from blood with phenol/chloroform extraction. Each LMNA exon and exon-intron boundaries were sequenced using the BigDye® Terminator v3.1 Cycle Sequencing Kit on a 3500 Genetic Analyzer (Applied Biosystems, Thermo Fisher Scientific, Waltham, MA). The primer sequences are available upon request.

All mutations were verified by restriction fragment length polymorphism (RFLP) in affected individuals and family members and the control group. Exons were PCR amplified and digested with endonucleases (p.R190P removes the FauI site in exon 3, p.W520R introduces theMspI site and p.T528R removes the RsaI site in exon 9).

**Bioinformatics tools**

Sequence variants were described according to the NCBI Reference Sequences NM_170708.3 and checked for population frequencies in Exome Sequencing Project, 1000 Genomes and Genome Aggregation Database. Multiple alignment of various orthologous sequences was built with Clustal Omega (http://www.ebi.ac.uk/Tools/msa/clustalo/). To predict the effects of amino acid substitutions on motif assembly, the wild-type (GenBank: AHU167294.1) and mutated sequences of lamin A/C were analysed in the Protein secondary structure prediction server JPred4 (7).

**Figure 1.** LMNA mutations detected in patients. (A) Representation of mutations localization in gene and protein domains; (B) Mutation detection by DNA sequencing. Heterozygosity is revealed as two overlapping peaks; (C) Illustration of the evolutionary conservation of residues associated with identified mutations located in the coding region of LMNA by multiple alignment of various orthologous sequences.

Symbol (*) indicates identical residues in all aligned sequences, (:) - conserved substitutions, (.) - semi-conserved substitution.
Results

LMNA exon sequencing led to the identification of different heterozygous mutations in three unrelated patients: p.R190P (c.569G > C, rs267607571), p.W520R (c.1558T > C, rs267607557) and p.T528R (c.1583C > G, rs57629361) (Fig. 1A,B). Detailed clinical characteristics of the patients are presented in Table I. The evolutionary conservation of residues was confirmed by multiple alignment of the region surrounding these variants against various orthologous sequences (Fig. 1C).

**Patient 1.** The proband is a 24-year-old woman. The initial symptoms of DCM appeared when she was 23 (Tab. I). There was no family history of DCM or sudden cardiac death. Clinical presentation manifested in atrial fibrillation and atrioventricular block (AVB). Complete heart block developed suddenly and quickly within three months after her first symptoms (dyspnea and weakness). No visible pathological changes of the coronary arteries were found by coronary angiography. Cardiac magnetic resonance imaging showed dilatation of the heart chambers and systolic biventricular dysfunction. The cardioverter-defibrillator implantation and pharmacological therapy did not stop heart failure from progressing, so orthotopic heart transplantation was performed. Neurological examination showed hyperlordosis, mild quadriiceps hypotrophy, hypertrophy of calf muscles without reduced limb strength. Reflexes and nerve conduction were normal. Serum creatine phosphokinase level elevated up to 293 U/L (normal range 24-190 U/L) (Tab. I).

The missense p.R190P at exon 3 of the LMNA gene was identified in patient 1. First-degree relatives did not have cardiovascular disease or skeletal muscle involvement. Family genotyping showed that p.R190P occurred de novo (Fig. 2). To estimate the pathogenicity of the missense variant, population screening was performed. No mutation in LMNA gene was detected in the control group consisting of 315 adult subjects.

Mutation p.R190P is located in the α-helical rod domain that forms a dimeric coiled coil (CC) necessary for creating lamin network. The JPred4 server was chosen for evaluating CC formation. A low probability of regular

**Table I. Clinical characteristic of patients.**

<table>
<thead>
<tr>
<th>Individual</th>
<th>Cardiac phenotype, (age at onset)</th>
<th>Systolic function, LVEF*</th>
<th>ECG characteristics in series</th>
<th>Neurological phenotype (age at onset)</th>
<th>Dominant muscle defect</th>
<th>sCPK level, u/l (age)</th>
<th>PM/ICD implantation (age)</th>
<th>HTx (age)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patient 1</td>
<td>DCM (23)</td>
<td>27%</td>
<td>SB, AVB, SSS, AF, RBBB, VES, CHB, nsVT</td>
<td>Subclinical (21)</td>
<td>Quadriiceps minimal hypotrophy</td>
<td>293 (23)</td>
<td>ICD (23)</td>
<td>24</td>
</tr>
<tr>
<td>Patient 2</td>
<td>DCM (27)</td>
<td>25%</td>
<td>AVB, AF, LBBB, CHB, nsVT</td>
<td>LGMD1B (27)</td>
<td>The limb-girdle pattern of weakness</td>
<td>784 (30)</td>
<td>PM (27) ICD (30)</td>
<td>32</td>
</tr>
<tr>
<td>Patient 3</td>
<td>DCM (40)</td>
<td>44%</td>
<td>AF, AVB, CHB, sVT</td>
<td>AD-EDMD (5)</td>
<td>Proximal muscles, scapular-humeroperoneal pattern, early contractures</td>
<td>471 (40)</td>
<td>PM (40) ICD (46)</td>
<td>-</td>
</tr>
</tbody>
</table>

LVEF refers to the first clinical admission. AD-EDMD: autosomal dominant Emery-Dreifuss muscular dystrophy; AF: atrial fibrillation; AVB: atrioventricular block; CHB: complete heart block; DCM: dilated cardiomyopathy; ECG: electrocardiogram; HTx: heart transplantation; ICD: implantable cardioverter defibrillator; LBBB: left bundle branch block; LGMD1B: limb-girdle muscular dystrophy type 1B; LVEF: left ventricular ejection fraction; nsVT: nonsustained ventricular tachycardia; PM: pacemaker; RBBB: right bundle branch block; SB: sinus bradycardia; sCPK: serum creatine phosphokinase, normal level 24-190 U/L; SSS: sick sinus syndrome; sVT: sustained ventricular tachycardia; VES: ventricular extrasystoles.

Figure 2. Pedigrees of patient’s families. Squares indicate males, circles – females, open symbols – unaffected members, solid symbol – clinically affected subjects, slanted bars – deceased individuals, the black filled dot within symbol – mutation carrier. The arrow denotes the proband. Symbols (+) and (-) indicate LMNA mutation carriers and non-carriers, respectively. The absence of such symbols denotes that no DNA was available for analysis.
coiled-coil assembly for P190 was shown: less than 50%. This is particularly low in comparison to R190, which has a probability of more than 90% (Fig. 3).

Patient 2. The proband is a 34-year-old woman. The first symptoms of AVB appeared when she was 27. At this period, no signs of heart dilatation were observed. During the next 3 years, heart failure symptoms progressed rapidly. Negative myocardial remodeling and progressive heart failure were observed despite the biventricular resynchronization therapy with optimal medical management and prescribed heart transplantation. The proband suffered from slight limb muscle weakness since childhood. Progressive skeletal muscle pain and weak, lower-limb muscle hypotrophy developed simultaneously with heart failure symptoms. LGMD was diagnosed when limb-girdle wasting with symmetric weakness predominantly affecting the proximal legs and arms distinctly manifested.

Patient 2 is a carrier of the p.W520R mutation. Family genotyping did not detect p.W520R in the patient’s father or sister. The mother’s death was not associated with cardiac diseases. There was no family history of DCM, skeletal muscle involvement or sudden cardiac death. The mutation was inherited by a daughter (Fig. 2), still asymptomatic except for a high serum CPK level.

Patient 3. This case is characterised by atypical clinical presentations of EDMD. Very severe muscular dystrophy and mild DCM were observed in the proband, a 47-year-old man. Wasting and weakness of the upper- and lower-limb muscles were slowly progressing from the age of 5. During adolescence, EDMD manifested through contractures of the elbows and the Achilles’ tendons; muscular dystrophy affected the arms, legs, spine, face, and neck. On the third decade of his life, a progressive proximal muscular atrophy with multiple contractures has developed. No heart disorder presented in the patient before the age of 40. The first cardiac sign was syncope caused by a complete heart block. Echocardiography showed DCM: mild left ventricular dilatation with a decrease of ejection fraction. A permanent pacemaker was implanted.

The mutation p.T528R at exon 9 of the LMNA gene was identified in patient 3. Genetic testing of his first-degree relatives confirmed a de novo origin of the mutation. The proband has an affected child, a son diagnosed with a severe form of EDMD. Informed consent was not obtained from the son, so LMNA analysis was not performed.

Discussion

The p.R190P carrier is unique. Its detailed clinical manifestation was reported before (8). In this article, we presented data supporting its pathogenicity. We consider the variant p.R190P as pathogenic, leading to delated cardiomyopathy and conduction defects. Its de novo occurrence led to the disease development that was not previously detected in the proband family. The mutation alters an amino acid residue in the highly conserved position where another missense changes have been determined as ‘pathogenic’ before. The mutation was not detected in the control group consisting of 315 adult subjects and was absent in publicly available population databases.
Codon 190 is located in the protein α-helical rod domain that forms a simple dimeric left-handed coiled coil (CC), which is the building block of higher-order lamin structures. The studies of LMNA mutations in the rod domain confirmed their impact on protein dimerization and assembly both in vitro and in vivo (14). In general, proline is not typical for CC and is known as the ‘helix breaker.’ We suppose its intercalation in position 190 of laminas could critically destabilize the CC structure and abolish the assembly of the normal nuclear lamina (Fig. 4).

The genetic testing allowed specifying the diagnosis of patient 2 to LGMD type 1B. This pathology form is accompanied by severe cardiomyopathy and potentially life-threatening cardiac arrhythmias presented from the first to the fourth decade of life. Our patient with LGMD predominantly suffered from cardiomyopathy with slight skeletal muscle involvement. These features became the basis for the search for LMNA mutation. We suppose the substitution of aromatic tryptophan to arginine residue, p.W520R, was crucial in LGMD development in patient 2. Codon 520 can be rightfully considered as the hot spot of LMNA gene. Several case reports associated with EDMD or LGMD have described other substitutions in this position: p.W520S (15) and p.W520G (16).

The mutation p.T528R caused severe muscular dystrophy without heart disease manifestation for an extended period in our patient 3. The laminopathy was suspected only at age of 40 when the specific cardiac pathology manifested. The genetic investigation verified the diagnosis of autosomal-dominant EDMD type 2. We note that cardiomyopathy in other described cases of EDMD associated with p.T528R was manifested before the age of 30. The early symptoms of heart failure were shortness of breath, atrial fibrillation and sinus tachycardia at the age of 12-23 years (17-20). Zhang et al. (2015) observed this variant in two patients with EDMD and showed positive segregation in their families, supporting pathogenicity for p.T528R (20).

Residue W520 and T528 are composed of the lamin C-terminal domain with an immunoglobulin-like fold (Ig-fold). The W520 is a unique hydrophobic residue, which is involved in the structuring and the positioning of the largest loop of Ig-fold. Residue T528 is composed of the β-sandwich core and stabilizes its conformation (21). Substitutions in these crucial positions will change the balance of weak and strong interactions interfere with the stability, folding and biochemical properties of Ig-domain.

In summary, this article presents the LMNA mutations identified in unrelated patients suffering from DCM with conduction defects, autosomal-dominant EDMD and LGMD type 1B. We consider the missense variants p.R190Q, p.T528R and p.W520R as pathogenic, leading to dilatation cardiomyopathy. They were not detected in the ethnically matched control group and publicly available population databases. Their de novo occurrence led to the disease development that was not previously detected in the extended family. There are well-characterised mutations at the same codons associated with laminopathies. Previously reported cases with LGMD and EDMD demonstrated positive family segregation, supporting pathogenicity for p.W520R and p.T528R. Patients with LMNA mutations have a poor prognosis, a higher risk of sudden cardiac death. There is no specific treatment for laminopathies because their mechanism in humans is still unclear. The experience one can get while matching the definite laminopathy symptoms with the mutations re-
revealed in the patients LMNA gene, in any case, bring us closer to understanding the genetic basis of disease. Linkage analyses in affected families allow for prognosis and medication steps for mutation carriers.

Acknowledgments

The authors are grateful to the families involved in this study.

References

Is the epicardial left ventricular lead implantation an alternative approach to percutaneous attempt in patients with Steinert disease? A case report

ANDREA ANTONIO PAPA1,2, ANNA RAGO1, ROBERTA PETILLO2, PAOLA D’AMBROSIO2, MARIANNA SCUTIFERO2, MARISA DE FEO3, CIRIO MAIELLO4 AND ALBERTO PALLADINO2

1 Department of Cardiothoracic Sciences, Chair of Cardiology, Monaldi Hospital, University of Campania “L. Vanvitelli”; 2 Cardiomyology and Medical Genetics, University Hospital of Campania “L. Vanvitelli”; 3 Department of Cardiothoracic Sciences, Unit of Cardiac Surgery, Monaldi Hospital; 4 Transplant Surgery Unit, AORN Ospedali dei Colli, Monaldi Hospital, Naples, Italy

Steinert’s disease or myotonic dystrophy type 1 (DM1) is an autosomal dominant multisystemic disorder characterized by myotonia, muscle and facial weakness, cataracts, cognitive, endocrine and gastrointestinal involvement, and cardiac conduction abnormalities. Although mild myocardial dysfunction may be detected in this syndrome with age, overt myocardial dysfunction with heart failure is not frequent. Cardiac resynchronization therapy is an effective treatment to improve morbidity and reduce mortality in patients with DM1 showing intraventricular conduction delay and/or congestive heart failure. We report the case of a patient with Steinert disease showing an early onset ventricular dysfunction due to chronic right ventricular apical pacing, in which an epicardial left ventricular lead implantation was performed following the failure of the percutaneous attempt. As no relief in symptoms of heart failure, nor an improvement of left ventricular ejection fraction and reverse remodelling was observed six months later, the patient was addressed to the heart transplantation.

Key words: cardiac resynchronization, epicardial left ventricular implantation, Steinert disease

Introduction

Myotonic dystrophy type 1 (DM1) or Steinert’s disease, is the most common muscular dystrophy in adult life with an estimated prevalence of 1/8000. Cardiac involvement, including conduction abnormalities with arrhythmias and conduction disorders, contributes significantly to the morbidity and mortality of the disease. It is recorded in about 80% of cases, and may precede the involvement of skeletal muscles (1-3). The characteristic impairment of His-Purkinje system is the most common cardiac abnormality. Mild ventricular dysfunction has also been reported associated with conduction disorders, but severe ventricular systolic dysfunction is not frequent and usually occurs late in the course of the disease as the final stage of cardiomyopathy (1). Cardiac resynchronization therapy (CRT) is able to restore physiological pattern of ventricular depolarization, resulting in reduction of mitral regurgitation and improvement of left ventricular (LV) systolic function (4-6). CRT has demonstrated reduction in morbidity and mortality in patients with severe refractory heart failure (HF) and intraventricular conduction delay (4-6). The technique of choice for left ventricular pacing in ventricular resynchronization is the insertion of a lead through the coronary sinus, into the posterolateral vein. The epicardial placement of ventricular leads is considered at present, a salvage technique for patients in whom the percutaneous procedure fails (7).

We report the case of a patient with Steinert disease showing an early onset ventricular dysfunction caused by chronic right ventricular apical pacing, in which an epicardial left ventricular lead implantation was performed following the failure of the standard percutaneous attempt. As no relief in symptoms of heart failure, nor
an improvement of left ventricular ejection fraction and reverse remodelling was observed six month later, the patient has been addressed to the heart transplantation.

**Case report**

A 43-year-old man – affected by Steinert disease and regularly followed at Cardiomyology and Medical Genetics Service since the time of his diagnosis (2003) – was hospitalised for an exacerbation of signs and symptoms of congestive heart failure [fatigue, muscle weakness, dyspnea, ortophnea, edema and palpitations, New York Heart Association (NYHA) class III]. His blood pressure (BP) was 100/60 mmHg and heart rate (HR) 60/bpm. Crackles at the basal field of lungs and pretibial edema were detected. Chest X-ray revealed cardiac dilation and pulmonary congestion.

The diagnosis of DM1, at first based on the family history (one affected brother) and clinical features (myotonic phenomenon, mild distal skeletal muscle dysfunction, cataract, gastrointestinal disturbances, endocrine deficiency), was subsequently confirmed by molecular testing, that showed a pathological expansion of CTG triplets (E1 class). In 2005, a bicameral pacemaker (PM) was implanted because evidence of first degree (PR interval ≥ 255ms) plus second-degree type2 atrio-ventricular block (8-13), and concomitant paroxysmal atrial flutter (AF) episodes. The implant was made according to the current guidelines (14) and was followed by an improvement of symptoms and quality of life. To be noted that atrial arrhythmias are not rare in this population (15-17).

In 2013, the PM – according to the current guidelines (18) – was uploaded to a cardioverter defibrillator (ICD) due to the finding of not sustained ventricular tachycardia (NSVT) in pacemaker stored electrograms to prevent the high risk of sudden cardiac death, frequently observed in these patients as in others muscular dystrophies (19). The ICD was placed in the right position, because of the occlusion of left subclavian vein (20-22).

In 2016 during a routine clinical and instrumental follow-up, signs of congestive heart failure (CHF) were detected. The ECG showed a sinus rhythm and a wide QRS interval (165 ms) due to constant right ventricular apical pacing (Fig. 1). Transthoracic echocardiography showed dilation of the heart (left ventricular end-diastolic diameter – LVEDD – was 7.4 cm), left systolic dysfunction and overt intra- and inter-ventricular asynchrony. The ejection fraction (EF), calculated by the Simpson and Teichholz method, was 25% (Fig. 2).

The interrogation of ICD revealed absence of intrinsic spontaneous ventricular rhythm, not sustained paroxysmal episodes of atrial flutter/fibrillation and ventricular tachycardias and no episodes of malignant sustained ventricular arrhythmias requiring device intervention. According to the current guidelines (23), his medical therapy was adjusted and included aggressive loop diuretic therapy, β-blockers, spironolactone and ACE inhibitors. In order to rule out an ischemic aetiology of dilated cardiomyopathy and consequent heart failure, a diagnostic coronary angiography was performed showing normal coronary arteries. Despite the aggressive medical therapy the patient experienced two episodes of acute heart failure over one year period, posing the indication for cardiac resynchronization therapy by a biventricular ICD-CRT (24). Before the intervention, a right subclavian venogram was performed which revealed a long segment of occlusion; any attempt to recanalise the right subclavian vein percutaneously failed. Venous stenosis or occlusion due to thrombosis/fibrosis resulting from the presence of the lead is a frequent side-effect in patients implanted with devices. In these cases, an epicardial approach is planned.

**Technical procedure**

The procedure was performed after written informed consent. Left antero-lateral thoracotomy was performed...
Is the epicardial left ventricular lead implantation an alternative approach to percutaneous attempt in patients with Steinert disease?

along the fourth intercostal space under general anesthesia. The patient was placed in a 45° rotation to the right side. A 3- to 4-cm long minithoracotomy was performed through the fourth intercostal space between the anterior and mid-axillary line.

The pericardium was opened longitudinally anterior to the phrenic nerve and suspended with traction sutures to better expose the lateral wall. The epicardial lead (bipolar) was fixed at the anterolateral wall of LV. Electrical parameters were measured to verify the correct positioning of the new leads. Once a site with satisfactory pacing threshold was identified (impedance > 200 Ω and < 2000 Ω, sensing > 5 mV and pacing threshold measured at 0.5 ms < 2.0 V), the lead was sewn with 5/0 polypropylene sutures. The connector of the lead was tunelled to the ICD-CRT device pocket in the right pre-pectoral region. The previous endocardial right ventricular defibrillation lead was connected to the ICD-CRT generator (Fig. 3). The patient was extubated in the operating room and observed in the cardiac surgery recovery unit for 24 hours.

Patient’s follow-up

The post-operative follow up included the assessment of NYHA functional class, ECG with determination of QRS duration and echocardiography. Left ventricular ejection fraction, left ventricular end-diastolic dimension and severity of mitral regurgitation (MR) values were collected to analyse the effect of CRT via epicardial LV lead placement on reverse ventricular remodelling. One month later an optimization of the atrio-ventricular and inter-ventricular intervals during cardiac resynchronisation was performed by both ECG and echocardiogram.

At six-months follow-up, no relief of symptoms was reported by the patient. In that occasion ECG revealed paced biventricular rhythm with a still wide QRS interval (150 ms, Fig. 4), though of reduced size compared to the previous one, and no changes in the repolarization dispersion time. Despite an adequate biventricular pacing the patient remains in NYHA class-III and experienced a further episode of acute heart failure requiring hospitalization. The echocardiogram didn’t show an improvement of EF and LV stroke volume (Fig. 5). The ICD analysis showed no significant modification of the electrical parameters, paroxysmal atipical atrial flutter/fibrillation and 98% biventricular pacing rhythm. The patient experienced one episode of slow sustained monomorphic ventricular tachycardia (140 bpm), recognized in monitoring zone of the device, which required external electrical cardioversion.

Discussion

Conduction abnormalities are the most frequent finding of cardiac involvement in patients with DM1 and minor conduction defects can be present in early stages of the disease (1, 2, 25-27). More severe conduction defects may be cause of shortness of breath, dizziness, faint-

![Figure 3. Chest X-ray postero-anterior (PA) view showing leads and ICD-CRT generator placement.](image)

![Figure 4. Post-implant ECG showing sinus rhythm with QRS different morphology (compared to the pre-implant one), due to constant biventricular pacing.](image)

![Figure 5. Echocardiographic findings after 6-month ICD-CRT implantation. Please note that both heart dimensions and ejection fraction are unchanged. A blood clot (thrombus) in the left apical ventricle can be observed (white arrow).](image)
ing, syncope, and even of sudden death. Left ventricular dilatation with overt systolic dysfunction is not frequent; however when present they may be more prominent than the muscle complaint. Cardiac symptoms generally occur later compared to the skeletal muscle weakness, but sometimes they may be the initial manifestation of the disease (1, 2, 25). In patient here reported, the early onset of heart failure could be related to the electromechanical delay caused by both intra- and inter-ventricular asynchrony due to chronic right apical pacing; the latter leads to regional structural changes causing a uncoordinated heart contraction that in turn accelerates the progression of the heart failure (28). Beside advances in the optimal medical treatment, strategies for medically refractory symptomatic advanced heart failure have emerged, including cardiac resynchronization therapy. Patients with NYHA class III or IV, with EF 35% or less, sinus rhythm with a QRS duration ≥ 130 ms and left bundle branch block (LBBB) or a QRS duration ≥ 150 ms irrespective of the QRS morphology, are eligible to receive a cardiac resynchronization therapy, according to the current guidelines (23). Basing on the progression of LV dysfunction, AV conduction disturbances and the frequent occurrence of ventricular tachyarrhythmia, Said et al. (29) hypothesized a role for biventricular ICD in patients with DM1 who need a permanent pacemaker implantation. Two previous papers (7, 30) reported an improvement in symptoms of heart failure, LVEF and reverse remodelling in one patient with DM1 showing an early onset ventricular pacing dysfunction secondary to a complete LBBB by this approach. However, a clear consensus about biventricular pacing or the usage of ICD does not exist for this kind of patients.

The “standard of care” of left lead implantation for CRT still remains the less invasive transvenous approach (31). However, several issues may result in failed transvenous implantation of the LV lead such as anatomical limitations due to occlusion of the subclavian vein or the superior vena cava, or an abnormal anatomy of the coronary sinus. Furthermore, lead-related issues such as lead instability with repeated dislodgement, phrenic nerve stimulation despite electrical or physical optimization, or systemic conditions such as endocarditis may contribute to failed transvenous LV lead implantation (31). In these cases, the surgical placement of an epicardial LV lead is required with satisfactory long-term results (32).

Conclusions

The case here reported is the first patient with DM1 in which an epicardial left ventricular lead implantation was used for cardiac resynchronization therapy after failure of percutaneous attempt. At six-months follow-up, based on this experience, the epicardial CRT did not induce either symptom relief, nor improvement of the ejection fraction or reduction of the arrhythmic risk. A possible explanation of the heart failure in this patient may be the prolonged apical pacing; further studies are in progress to determine the consequences of long-term constant apical pacing in patients affected by Myotonic Dystrophy type 1.

References

Is the epicardial left ventricular lead implantation an alternative approach to percutaneous attempt in patients with Steinert disease?


Complete resolution of left atrial appendage thrombosis with oral dabigatran etexilate in a patient with Myotonic Dystrophy type 1 and atrial fibrillation

Anna Rago1, Andrea Antonio Papa1,2, Giulia Arena3, Marco Mosella4, Antonio Cassese1, Alberto Palladino2 and Paolo Golino1

1 Department of Cardiology, University of Campania “L. Vanvitelli”, Monaldi Hospital, Naples, Italy; 2 Cardiomyology and Medical Genetics, University Hospital “L. Vanvitelli”, Naples, Italy; 3 Department of Cardiology, Umberto I Hospital, Nocera, Salerno, Italy; 4 Division of Pneumology, Department of Clinical Medicine and Surgery, “Federico II” University, Monaldi Hospital, Naples, Italy

Myotonic Dystrophy type 1 (DM1) is the most common muscular dystrophy in adult life characterized by muscle dysfunction and cardiac conduction abnormalities. Atrial fibrillation frequently occurs in DM1 patients. It’s related to the discontinuous and inhomogeneous propagation of sinus impulses and to the prolongation of atrial conduction time, caused by progressive fibrosis and fatty replacement of the myocardium. AF predisposes to a hyper-coagulable state and to an increased risk of thromboembolism. We report the first case of complete resolution of left atrial appendage thrombosis with oral dabigatran etexilate in a myotonic dystrophy type 1 patient with atrial fibrillation scheduled for transesophageal echocardiogram-guided direct current cardioversion.

Key-words: myotonic dystrophy, atrial fibrillation, dabigatran etexilate, atrial thrombus

Introduction

Myotonic dystrophy type 1 (DM1) is the most common muscular dystrophy in adult life with an incidence of 1:8000 births and a worldwide prevalence ranging from 2.1 to 14.3/100.000 inhabitants. Cardiac involvement is noticed in about 80% of cases, and it often precedes the skeletal muscle one (1). Paroxysmal atrial arrhythmias (atrial fibrillation, atrial flutter, atrial tachycardia) frequently occur in DM1 patients with a prevalence up to 25% (2) and seem to increase mortality in this population (3). Modern pacemakers (PMs) and implantable cardiac defibrillators (ICDs) include detailed algorithms and functions to facilitate the diagnosis and management of frequent paroxysmal atrial tachy-arrhythmias often undetected during conventional clinical follow-up (4-11). Atrial fibrillation (AF) predisposes to a hypercoagulable state and an increased risk of thromboembolism (TE) (12, 13). The incidence of left atrial appendage thrombosis before direct current cardioversion (DCC) has been widely studied in AF population, ranging from 6 to 18% (14, 15). Non-Vitamin K Antagonist oral anticoagulants (NOAC) are increasingly used for the prevention and treatment of thrombi formation owing to the inherent limitations of Vitamin K antagonist oral anticoagulants (VKAs) (16). We report the first case of a left atrial appendage thrombosis effectively treated by dabigatran etexilate, a direct inhibitor of thrombin, in a DM1 patient with AF scheduled for transesophageal echocardiogram (TEE)-guided direct current cardioversion (DCC).

Case report

A 45-year-old DM1 woman with arterial hypertension, previously implanted with a dual chambers pacemaker for advanced atrioventricular block, came to our observation for PM check and cardiologic therapy optimization before cataract surgery. She was taking perindopril (4 mg/die) and magnesium pidolate (2.25 g/die).
She referred a recent onset of palpitations and dyspnea. Standard (12-lead electrocardiogram) ECG confirmed the diagnosis of atrial fibrillation with a mean ventricular rate of 160 bpm (Fig. 1). PM interrogation showed atrial high rate electrograms (AHRE) faster than 220 bpm, that lasted longer than 5 minutes with irregularity and incoherence of RR intervals (Fig. 2) and arose five days before the cardiologic evaluation. Transthoracic echocardiogram showed a slightly reduced left ventricular systolic function (Simpson’s biplane ejection fraction: 48%) and a mild left atrial enlargement (left atrial volume index: 29 mL/m²). Considering the patients’ symptoms and the need to restore sinus rhythm before surgical procedure, a TEE-guided DCC was performed, which showed the presence of a thrombus in left atrial appendage (Fig. 3). The patient started a beta-blocker therapy for rate control (bisoprolol 2.5 mg/die) and oral anticoagulant therapy (warfarin 5 mg/die) to dissolve the thrombus and prevent the risk of systemic thrombo-embolic events. However, at one-month follow-up, due to a non-optimal response to warfarin therapy, evaluated by the International Normalized Ratio (INR) of the prothrombin time, a switch form VKA to NOAC therapy with dabigatran was performed at a dosage of 150 mg/bid. Eight weeks after, TEE revealed the complete resolution of the left atrial appendage thrombus (Fig. 4), allowing us to perform a safe and successful direct current cardioversion, that restored the sinus rhythm at 65 bpm. The therapy with dabigatran was prolonged for 4 weeks after cardioversion due to the high risk of thromboembolic events (CHA2DS2-Vasc Score: 2). At the date, twelve months after DCC procedure, no bleeding events or side-effects are reported.

**Discussion**

Cardiac involvement in DM1 patients occurs as a degenerative process with progressive fibrosis and fatty replacement not only limited to the specialized conduction system, but also extended to initially unaffected areas of the atrial myocardium (17). This anatomo-pathological substrate, causing the discontinuous and inhomogeneous propagation of sinus impulses and the prolongation of atrial conduction time, may facilitate the onset and perpetuation of atrial arrhythmias in these patients (18-24), as usually happens in other clinical conditions (25-30). AF is one of the most common supraventricular arrhythmias observed in DM1 population, characterized by chaotic and uncoordinated atrial activity which predisposes to a hypercoagulable state and an increased risk of TE (12, 13). DCC quickly and effectively converts AF...
to sinus rhythm; however, it carries an inherent risk of stroke, which is substantially reduced by the administration of anticoagulation therapy. An early initiation of such therapy is important in all patients scheduled for cardioversion. Patients who have been in AF for periods longer than 48 h should start oral anticoagulation therapy at least 3 weeks before cardioversion and will continue it for at least 4 weeks afterwards (31). However, the difficulties in achieving an optimal anticoagulation with conventional warfarin therapy, likely related to several factors such as the slow onset of action, variable pharmacologic effects, numerous food and drug interactions and periodic closely target INR monitoring (32) make it difficult the therapeutic management in clinical practice and reduce the real-life patients’ compliance. All these challenges have prompted an extensive research and developed NOAC, now available for stroke prevention in AF patients and used in various clinical settings (33-38). Dabigatran etexilate, a direct inhibitor of thrombin, emerged as the first new generation oral anticoagulants potentially able to replace warfarin in preventing arterial TE in patients with AF (39-41). A post-hoc analysis of the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) study in patients who underwent cardioversion with or without TEE guidance, showed that dabigatran treatment has a low and comparable frequency of adverse events compared to warfarin (42). These results were confirmed by a long term propensity score matched study in real world setting (43). The potential thrombolytic effect of dabigatran has been previously described (43, 44) as it is able to create a easier and faster anticoagulation milieu while inhibiting thrombin binding to fibrin and fibrin degradation products. In contrast warfarin anticoagulation, in its loading phase, could also exert a transient thrombogenic action (45).

**Conclusions**

The present case is the first report of a complete left atrial appendage thrombosis resolution obtained by oral dabigatran etexilate in a DM1 patient with AF, scheduled for TEE guided direct electrical cardioversion. The use of NOAC therapy should be particularly useful in this population of patients, for their variable cognitive impairment and consequent poor compliance with periodic INR monitoring.

**References**


OBITUARY

Professor Giovanni Nigro 
(1931-2017)

Giovanni Nigro (born 24 April 1931) died at his home in Naples on 13 October 2017. After graduating in Medicine and Surgery from the University of Naples “Federico II” in 1954 at the age of 23, he was invited to Sweden, where he had the privilege to work with Gunnar Biörck and Hugo Theorell, recipient in 1955 of the Nobel Prize in Medicine for his studies on myoglobin, cytochrome c and the respiratory chain.

At only 29 years of age he became the youngest Professor of Internal Medicine in Italy, and a few years later was also appointed Professor of Clinical Biochemistry. Following his return from Sweden until his retirement, he worked tirelessly at the University of Naples, first as an unpaid teaching assistant, then as Professor of Special Medical Pathology and later Professor of Therapy.

During his long academic career, he served in key roles on the Department Council, the Department Executive Board, and the University Council, contributing to the drafting of the Statute of the Second University of Naples – now the University of Campania “Luigi Vanvitelli” – with a true and increasingly rare spirit of public service.

His interest in muscle diseases stemmed from an encounter with a young girl suffering from a muscle disorder while working as a university teaching assistant.

In 1961, he attended a conference on muscular diseases in Trieste – organized by a patient – after reading about it in the newspaper. There, he learned of the Italian Union for the Fight against Muscular Dystrophy (UILDM) and returned to Naples determined to set up a local branch of the association to help families of affected children. Over the following years he served as National President of the UILDM from 1979 to 1986, and chaired its Medical-Scientific Committee from 1984 to 1990.

In 1971 he opened the first rehabilitation center in Campania for patients with muscle conditions, carrying out the last request of a dystrophic boy who had entrusted him with the entire contents of his piggy bank. Named in memory of the boy, the Gaetano Torre Center for Muscular Diseases is still running today, and over the years has supported about 70 families, helping unemployed parents of children with muscular dystrophy.

In 1976 he set up first Center of Cardiomyology and Myology at the Naples University Hospital, which went on to become a multi-speciality department in 1980.

In 1981 he organized the first international meeting on muscle diseases in Naples, attended by world-renowned researchers in the field.

In 1985 he invited Prof. Yves Rideau from the University of Poitiers to Naples University so that young Italian Duchenne patients might benefit from his innovative surgical-orthopedic therapy.

In 1989, as Chair of the UILDM’s Medical-Scientific Commission, he imported the Téléthon event run by the French Association against Myopathies (AFM) to Italy, inaugurating the very first Italian Téléthon Marathon, now in its 28th year.

He was one of the founder members of the European Neuromuscular Centre, set up in 1992, and served on both...
its Executive and Research Committees, later becoming one of the organization’s honorary members.

In 1993 he established the Mediterranean Society of Myology (MSM) in Ischia, uniting members from 22 different countries, with the aim of bringing together experts in striated muscle diseases and neuromuscular disorders from across the Mediterranean area, fostering collaborative medical and biological research, holding scientific meetings, sponsoring a journal for the publication of scientific papers, and creating a Mediterranean-wide medical network for muscle diseases.

In 1995 he established the “Gaetano Conte Prize” in honor of the Neapolitan physician who in 1836 – 32 years before Duchenne de Boulogne – first described two patients with muscle degeneration. The prize is awarded to distinguished scientists working in the field of muscular dystrophies. In the same year he set up the World Muscle Society (WMS) in Bologna together with Victor Dubowitz and Luciano Merlini, and was one of the founder members of the Italian Association of Myology (AIM), created in 2000.

His name is inextricably linked with ground-breaking research in the field of cardiomyology – a term he himself coined – having first underlined how the heart may be a primary site of the dystrophic process in Duchenne patients. This was in 1976, 10 years before the discovery of the dystrophin gene. He was also one of the first to report cardiac involvement in Duchenne and Becker carriers, and heart disease as a major cause of death in numerous muscle disorders, such as myotonic dystrophies and Emery Dreifuss muscular dystrophies, if not properly diagnosed and treated.

Prof. Nigro remained active for many years after his retirement, working as editor-in-chief of the journal *Acta Myologica* and organizing conferences – including the World Federation of Neurology Congress in Naples in 2010, and MSM meetings in 2011, 2013 and 2015. The upcoming 13th MSM conference will be held in Cappadocia, Turkey, on 27-29 June 2018, and is dedicated to his memory.

He also continued to be actively involved in running the rehabilitation center he himself created, working on a voluntary basis as Medical Director until April 2016, as well as the G. Torre Association, where he served as an honorary member up until the day before his death.

On a more personal level, Prof. Nigro will be remembered for his quick wit, his ability to make light of difficult situations, his optimism, his capacity to come back stronger after each setback, his immediate empathy with patients and their families, and his pioneering approach. He was in no way jealous of his ideas or insights, and would always stress the importance of disseminating ideas, not their authorship.

Prof. Nigro leaves behind a great legacy, and his memory will live on among the tens of thousands of people – students, colleagues, patients and friends – who had the privilege of knowing him. We can only thank him for everything he taught us.

*Luisa Politano and Vincenzo Nigro*

The Pacini family and the editorial staff of Pacini Editore wish to remember Professor Giovanni Nigro for his precious collaboration in the realization of the Journal *Acta Myologica*.

His profound devotion as Editor-in-Chief affirmed the Journal as a high-profile scientific periodical in the national and international field.

His professionalism and correctness have allowed us to work in full harmony enriching our editorial experience.

It was always a pleasure to welcome him to our Company in Pisa.

*Patrizia Pacini*

*Managing Director*

*Pacini Editore srl*
NEWS FROM AROUND THE WORLD

AIM

Below the letter of the end year of the AIM President, Gabriele Siciliano, outlining the activities of the Association.

"Dear AIM Members,

It’s with a special feeling I’m sending to you the usual end of year message and my wish for a sparkle end of it and a very happy new year.

The first six months of the new year are the last of my triennial mandate, I am going to face them with a bit of melancholy for the usual exit phase but also with so much determination in bringing our Association towards always more ambitious and rewarding goals, cherishing the awareness of representing an united and enthusiastic working group. Therefore, this is not the time to make final summaries, rather I would like to stress the viability of our Association in its primary activities of disseminating knowledge, stimulating research and acting in favor of the patients.

The number of AIM members, especially young people, is further increased compared to the previous year, almost 20%.

We were involved in several educational events. We were regarded as advisory consultants at various institutional levels and authoritatively participated in research groups and national and international scientific events. Something more certainly is awaiting us from today to the next Genoa AIM Congress in June 2018.

After concluding to draft the new statute on December 12 (we updated and necessarily regularized some organizational and administrative aspects), we have been called, even as an affiliated association to the Italian Neurology Society, to work on drafting guidelines and clinical recommendations in our field of study, in compliance with the recently introduced legislation (the Gelli’s Law). It is my purpose to request your collaboration and your participation in working groups in this regard.

Another current topic is the increasing advisory role that institutions ask us to carry out in evaluating appropriateness of the new therapies for diseases of our interest, which is a fundamental and challenging task for all of us. This is part of the recognition of the role of our Association also in wider initiatives such as the one related to the ERN. In this regard, we were invited to a recent meeting in Rome, on 20 December, by authoritative representatives of the State-Regions conference on health issues.

The on-going project of the Coordination of Neuromuscular Patient Associations, in which we are involved as a technical partner, will continue albeit some difficulties (also economic for the smaller Associations) have slowed the legal recognition of this Coordination board. However, I firmly believe that we can not miss the opportunity to create synergies between doctors and the different patients’ associations.

In this view, we have been present at the audition with the Minister of Public Administration in September 27, and will participate at the Rare Disease Day on February 28 and, especially, at the next edition of the Neuromuscular Day, GMN2018, on March 10.

Our commitment will continue in divulging knowledge on muscle diseases and more generally in the matter of myology, in this organizing further scientific-and educational events, collaborating with other twin and related Associations, supporting research grants for young scientists, contributing to growth of our journal Acta Myologica.

With these brief notes I finish my message, I embrace all of you and I wish you a happy 2018."

MSM

The 13th Congress of the Mediterranean Society of Myology will be held in Turkey on 27-29 June 2018, organised by Prof. Haluk Topaloglu. The symposium was in the traditional two-days MSM format with selected topics (see brochure).

WMS

The 23rd International WMS Congress will be held in Mendoza, Argentina from 2 to 6 October 2018. The symposium will follow the traditional format with 3 selected topics:

• New developments in genetic and acquired disorders of the neuromuscular junction.
• Mitochondrial function and dysfunction in neuromuscular disorders: pathogenesis and therapies.
• Advances in the treatment of neuromuscular disorders.

One day of the symposium will be dedicated to each of the selected topics. Invited keynote speakers will summarize the state of the art on the selected topics, covering clinical, molecular and other aspects. The sessions will comprise selected oral papers and poster presentations with guided discussions. Contributions will also be welcome on new advances across the neuromuscular field. The 16th WMS Pre-Congress Teaching Course will be held on 1-2 October 2018. Please note only 45 places are available. Early booking is advised.
FORTHCOMING MEETINGS

2018

February 20-24

May 20-24
ISBER 2018 Annual Meeting & Exhibits. Dallas, Texas, USA. Information: website: http://meetings.isber.org

June 6-9
18th National Congress of Italian Association of Myology. Genua, Italy. Information: website: www.miologia.org

June 16-19
European Human Genetics Conference 2018. Milan, Italy. Information: website: conference@eshg.org

June 16-19

June 27-29
XIII Congress of Mediterranean Society of Myology. Avanos, Cappadocia, Turkey. Information: msm2018@flaptour.com.tr; htopalog@hacettepe.edu.tr

July 6-10

August 25-29
European Society of Cardiology (ESC). Munich, Germany. Information: website: https://www.escardio.org/

October 2-6

October 16-20
ASHG Annual Meeting. San Diego, CA, USA. Information: website: www.ashg.org

October 17-21

October 31- November 2

November 9-10
9th International Conference & Exhibition on Tissue Preservation and Biobanking at Atlanta, USA during, 2018. Information: website: http://biobanking.conferenceseries.com/

2019

May 2019

June 15-18
The European Human Genetics Conference 2019. Gothenburg, Sweden. Information: conference@eshg.org

September 24-28

October 22-26

To be announced

2020

June 6-9
The European Human Genetics Conference 2020. Berlin, Germany. Information: conference@eshg.org

October 27-31
ASHG Annual Meeting. San Diego, CA, USA. Information: website: www.ashg.org

To be announced
13th Meeting of the Mediterranean Society of Myology

This congress is memory of our late Professor Giovanni Nigro, one of the first pioneers for neuromuscular research in the Mediterranean area in connection with the

2nd Congress of the Turkish Neuromuscular Society

27-29 June 2018
Avanos, Cappadocia, Turkey

Topics of the congress: Limb-girdle muscular dystrophies, Advances in the field

Extra activity 1: 26-27 June 2018, Clinical neuromuscular course for physicians
Extra activity 2: 27 June 2018, Outcome measures course for physiotherapists
Dear Colleagues,

Thirty-six years ago, a group of researchers with people of the Mediterranean area, and created the Mediterranean Society of Myology in 1993, in Ischia. NeuroMuscular Center–ENMC (established in 1992 by Ysbrandt Portman, Reinhardt Rudel and myself) and the World Muscle Society (established in 1995 by Victor Dubowitz, Luciano Merlini and myself) The presence of the Turkish delegates has always been a successful event. Therefore I am very pleased and grateful to Prof. Haluk Topaloglu 30 April 2017 President of the Mediterranean Society of Myology 

Dear Colleagues, MSM has been originated in Italy, rapidly escalated, and within the past congresses of the Society, it will be our aim to bring researchers together with interest in basic and clinical science. The special topic for this congress has been chosen as “limb-girdle muscular dystrophies”. We shall try our best to create an done with the 2nd Cappadocia is an important tourism site in Turkey. We think that your visit to Cappadocia in the summer of 2018 will be rewarding academically and
Dear Colleagues,

Thirty-six years ago, a group of researchers with interest in the field of muscular dystrophies felt the need to promote a mutual cooperation among the people of the Mediterranean area, and created the Mediterranean Society of Myology in 1993, in Ischia. The initiative had a rapid success with the accession of the representatives of 22 Mediterranean Countries and was a model to establish other International Societies of Myology, such as the European NeuroMuscular Center–ENMC (established in 1992 by Ysbrandt Portman, Reinhardt Rudel and myself) and the World Muscle Society (established in 1995 by Victor Dubowitz, Luciano Merlini and myself).

The presence of the Turkish delegates has always enriched the value of the Society, and the organization of the 13th Congress attests their contribution.

Therefore I am very pleased and grateful to Prof. Haluk Topaloglu for accepting the task (and load) of the Congress organization, and I’m convinced it will be a successful event.

I hope that many of you will be present next year in Cappadocia.

Giovanni Nigro
30 April 2017

Dear Colleagues,

We invite you to attend the 13th Meeting of the Mediterranean Society of Myology (MSM) in Cappadocia, Turkey, June 27-29 2018. MSM has been originated in Italy, rapidly escalated, and within a decade has become an internationally renown group of enthusiasts. Bi-annual meetings have been traditional. With the spirit we have received from the past congresses of the Society, it will be our aim to bring researchers together with interest in basic and clinical science. The special topic for this congress has been chosen as “limbgirdle muscular dystrophies”. We shall try our best to create an exciting programme. This congress will jointly be done with the 2nd Turkish Myology meeting.

Cappadocia which was the population zone of the Assyrian civilization later has hosted the Hittite, Frig, Pers, Byzantine, Seljuk and Ottoman civilizations. Cappadocia is an important tourism site in Turkey.

We think that your visit to Cappadocia in the summer of 2018 will be rewarding academically and educationally, and also from the social aspects.

Prof. Haluk Topaloglu
President of the Mediterranean Society of Myology
COMMITTEES & KEY FIGURES

Congress Presidents
Giovanni Nigro, Haluk Topaloğlu

Local Organizing Committee
İpek Alemdaroğlu (secretary)
Hayat Erdem
Göknur Haliloğlu
Aysê Karaduman
Müjgan Sönmez
Beril Talim
Öznuu Yılmaz
Uluç Yiş

Board of the Mediterranean Society of Myology
President
H. Topaloğlu

Vice-Presidents
L.T. Middleton and G. Siciliano

Secretary
K. Christodoulou

Treasurer
L. Politano

Members
E. Abdel-Salam
M. Dalakas
F. Deymeer
F. Hentati
G. Meola
Y. Shapira
E. Tizzano
A. Toscano
J. Zidar

Board of the Turkish Neuromuscular Society
President
G. Kale

Secretary
M. Sönmez

Treasurer
Ö. Yılmaz

Members
A. Karaduman
B. Talim
H. Topaloğlu

13th Meeting of the Mediterranean Society of Myology in connection with the 2nd Congress of the Turkish Neuromuscular Society
28-30 June 2018 | Avanos, Cappadocia, Turkey
27 June 2018, Wednesday

19.00 – 19.30 Welcoming Lecture Followed by Reception

28 June 2018, Thursday

Limb-Girdle Dystrophies

Session 1. Genetics and Classification of Limb-Girdle Dystrophies

08.30 – 09.00 Classification and Pathophysiology
Marco Savarese, IT

09.00 – 09.30 Solve the Unsolved LGMDs: the Next Approach
Vincenzo Nigro, IT

09.30 – 10.00 The Gene Therapy Field in LGMD
Isabelle Richard, FR

10.00 – 10.30 Oculopharyngeal Muscular Dystrophy: From Bench to Bedside And Back Again
G Butler-Browne, FR

10.30 – 11.00 Break

Session 2. Clinical features of limb-girdle dystrophies

11.00 – 11.30 Clinical Features of Limb Girdle Dystrophies: an Overview
Jordi Diaz-Manera, SP

11.30 – 12.00 Metabolic Myopathies Mimicking Limb Girdle Dystrophy
Corrado Angelini, IT

12.00 – 12.30 Myofibrillar Myopathies
Duygu Selcen, USA and TR

12.30 – 13.00 Muscular Dystrophies with Mental Retardation
Haluk Topaloglu, TR

13.00 – 14.00 Lunch, Poster Viewing

14.00 – 15.30 Oral Presentations

15.30 – 16.00 Break

16.00 - 17.30 Posters

17.30 - 19.00 MSM General Assembly

20.00 – 24.00 Gala Dinner
Session 3. Advances and Therapies I

09.00 – 09.30 Genetic Diagnosis
Roula Cristodoulou, Cyprus

09.30 – 10.00 Laminopathies
Giselle Bonne, FR

10.00 – 10.30 Dysferlinopathy, Calpainopathy and Imaging
Giorgio Tasca, IT

10.30 – 11.00 Contribution of Muscle Biopsy in Diagnosis of LGMD in the Third Millennium
Rita Baresi, UK

11.00 – 11.30 Break

Session 4. Advances and therapies II

11.30 – 12.00 Future of genetics
Judith Melki, FR

12.00 – 12.30 Clinical and Molecular Heterogeneity in Limb-Girdle Muscular Dystrophies
Giacomo Comi, IT

12.30 – 13.00 Cardiac Involvement in Muscular Dystrophies: Contribution of the Naples’s School
Luisa Politano, IT

13.00 – 13.30 Treatment of Pompe Disease
Antonio Toscano, IT

13.30 – 14.30 Lunch, Poster Viewing

Session 5. Advances and therapies III

14.30 – 15.00 Update in spinal muscular atrophy treatment
Eugenio Mercuri, IT

15.00 – 15.30 Therapy of GNE Myopathy
Zohar Argov, IL

15.30 – 16.00 Duchenne Muscular Dystrophy: Future Perspectives
Yoram Nevo, IL

16.00 – 16.30 Sarcoglycanopathies, Therapeutic Approaches
Dorianna Sandona, IT

Closure of the meeting
Topics of the congress:
Limb-girdle muscular dystrophies
Advances in the field

Extra activity 1: 26-27 June 2018
Clinical neuromuscular course for physicians

Extra activity 2: 27 June 2018
Outcome measures course for physiotherapists

World Muscle Society members are highly specialised professionals active in the neuromuscular field, are on research for neuromuscular disorders or involved in the management of patients with these disorders.

<table>
<thead>
<tr>
<th>IMPORTANT DATES</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Beginning of Abstract Submission &amp; Registration</td>
<td>1 January 2018</td>
</tr>
<tr>
<td>Abstract Submission Deadline</td>
<td>30 April 2018</td>
</tr>
<tr>
<td>Early Bird Registration Deadline</td>
<td>30 April 2018</td>
</tr>
<tr>
<td>Pre-Congress Course Registration Deadline</td>
<td>15 May 2018</td>
</tr>
</tbody>
</table>
Cappadocia Region displays a beautiful combination of nature and history.

Some three million years ago, violent volcanic eruptions covered the plateau in this area with tufa, a soft stone comprised of lava, ash and mud. Subsequently, the wind and rain have eroded the brittle rock to form a spectacular surrealistic landscape of rock cones and capped pinnacles, called “fairy chimneys” that are painted in colors ranging from warm reds and gold to cool greens and grays. Fairy chimneys and carved houses and churches inside these formations and adorned these settlements with frescos, carrying the traces of the thousands of years of their civilizations. During Byzantine times, Christian chapels and monasteries were hollowed out of the rock, and later these dwellings served as refuge for Christians, persecuted by the Romans.

Göreme National Park and Cappadocia were placed on the UNESCO World Heritage List in 1985 as 7 parts: Göreme National Park, Derinkuyu Underground City, Kaymaklı Underground City, Karli Church, Theodore Church, Karain Güvercinlikleri (Karain Columbaries) and Soğanlı Archaeological Site.

Hot-air ballooning is very popular in Cappadocia and is available in Goreme. Daily hot-air balloon tours are organized in various concepts (from an hourly trip to lunch&dinner trips) and you can enjoy the fascinating view from the wonderful sky.
BENEFITS OF SPONSORS

- Sponsor companies will be show-casing in front of an elite, highly specialised professional group

- With its geographical outreach, Cappadocia is accessible for participants from all around Europe and Middle - Near East

- Participating companies will book their place in setting that will shape the future trends in development of drugs and equipment in the field

- Brand awareness for participating companies will be raised during the all event and will be set for a higher level for it will be a unique and vivid meeting

- Direct contact with trend-setters

- Direct exposure to possible clients
VOLUME XXXVI - CONTENTS

Issue N. 1 • March 2017

EDITORIAL
Giovanni Nigro .................................................. 1

ORIGINAL ARTICLES
Na MRI and myometry to compare eplerenone vs glucocorticoid treatment in Duchenne dystrophy
Philip A. Glemser, Heike Jaeger, Armin M. Nagel, Andreas E. Ziegler, David Simons, Heinz-Peter Schlemmer, Frank Lehmann-Horn, Karin Jurkat-Rott and Marc-André Weber .................................................. 2

Personality traits in patients with myotonic dystrophy type 2
Teodora Paunic, Stojan Peric, Aleksandra Parojcic, Dusanka Savic-Pavcivic, Milorad Vujnic, Jovan Pesovic, Ivana Basta, Dragana Lavrnic and Vidosava Rakocevic-Stojanovic ........................................ 14

Integrated care of muscular dystrophies in Italy. Part 1. Pharmacological treatment and rehabilitative interventions
Luisa Politano, Marianna Scutifero, Melania Patalano, Alessandra Sagliocchi, Antonella Zaccaro, Federica Civati, Erika Brighina, Gianluca Vita, Sonia Messina, Maria Sframeli, Maria Elena Lombardo, Roberta Scalise, Giulia Colia, Maria Cateruccia, Angela Berardinelli, Maria Chiara Motta, Alessandra Gaiani, Claudio Semplicini, Luca Bello, Guja Astrea, Giulia Ricci, Maria Grazia D’Angelo, Giuseppe Vita, Marika Pane, Adele D’Amico, Umberto Balottin, Corrado Angelini, Roberta Battini and Lorenza Magliano ........................................ 19

CASE REPORTS
Mitochondrial ANT-1 related adPEO leading to cognitive impairment: is there a link?
Costanza Simoncini, Gabriele Siciliano, Gloria Tognoni and Michelangelo Mancuso ........................................ 25

Congenital myasthenic syndrome: phenotypic variability in patients harbouring p.T159P mutation in CHRNE gene
Anna Ardissone, Isabella Moroni, Pia Bernasconi and Raffaella Brugnoni ........................................ 28

Effect on lung function of mouthpiece ventilation in Steinert disease. A case report
Anna Annunziata, Giuseppe Fiorentino and Antonio Esquinas ........................................ 33

NEWS FROM AROUND THE WORLD
AIM ................................................................ 36
GCA ................................................................ 36
MSM ................................................................ 36
WMS ................................................................ 36

Issue N. 2 • June 2017

ORIGINAL ARTICLE
Integrated care of muscular dystrophies in Italy. Part 2. Psychological treatments, social and welfare support, and financial costs
Lorenza Magliano, Marianna Scutifero, Melania Patalano, Alessandra Sagliocchi, Antonella Zaccaro, Federica Civati, Erika Brighina, Gianluca Vita, Sonia Messina, Maria Sframeli, Maria Elena Lombardo, Roberta Scalise, Giulia Colia, Maria Cateruccia, Angela Berardinelli, Maria Chiara Motta, Alessandra Gaiani, Claudio Semplicini, Luca Bello, Guja Astrea, Giulia Ricci, Maria Grazia D’Angelo, Giuseppe Vita, Marika Pane, Adele D’Amico, Umberto Balottin, Corrado Angelini, Roberta Battini and Luisa Politano ........................................ 41

PROCEEDINGS OF THE XVII CONGRESS OF THE ITALIAN ASSOCIATION OF MYOLOGY
Siracusa, Italy – May 31 - June 3, 2017
Scientific Programme ........................................... 51
Abstracts of oral communications ........................................... 67
Muscle Club Session ........................................... 80
Abstracts of poster communications ........................................... 82
Abstracts of Study Groups ........................................... 114
Author Index ........................................... 116

NEWS FROM AROUND THE WORLD
AIM ................................................................ 120
GCA ................................................................ 120
MSM ................................................................ 120
WMS ................................................................ 120

FORTHCOMING MEETINGS ........................................... 121
Instructions for Authors ........................................... 124

Issue N. 3 • September 2017

ORIGINAL ARTICLES
Myotonia permanens with Nav1.4-G1306E displays varied phenotypes during course of life
Frank Lehmann-Horn, Adele D’Amico, Enrico Bertini, Mauro LoMonaco, Luciano Merlini, Kevin R. Nelson, Heike Philippi, Gabriele Siciliano, Frank Spaans and Karin Jurkat-Rott ........................................ 125
Arhythmogenic right ventricular cardiomyopathy in Boxer dogs: the diagnosis as a link to the human disease
Annina S. Vischer, David J. Connolly, Caroline J. Coats, Virginia Luis Fuentes, William J. McKenna, Silvia Castelletti and Antonios A. Pantazis .......................... 135

Multi-slice MRI reveals heterogeneity in disease distribution along the length of muscle in Duchenne muscular dystrophy
Stephen M. Chrzanowski, Celine Baligand, Rebecca J. Willcocks, Jasjit Deol, Ilona Schmalfuss, Donovan J. Lott, Michael J. Daniels, Claudia Sesenac, Glenn A. Walter and Krista Vandenborne........................................ 151

Leber’s hereditary optic neuropathy (LHON) in an Apulian cohort of subjects
Angelica Bianco, Luigi Bisceglia, Paolo Trerotoli, Luciana Russo, Leonardo D'Agruma, Silvana Guerriero and Vittoria Petruzzella................. 163

CASE REPORTS
Bethlem myopathy in a Portuguese patient – case report
Ana Inês Martins, Cristina Marques, Jorge Pinto-Basto and Luís Negrão .................................................. 178

ERRATA CORRIGE ........................................... 182

NEWS FROM AROUND THE WORLD
AIM ............................................. 184
GCA ........................................... 184
MSM ........................................... 184
WMS ........................................... 184

FORTHCOMING MEETINGS .................. 185

Instructions for Authors ........................................... 189

Issue N. 4 • December 2017

ORIGINAL ARTICLES
Differential diagnosis of vacuolar muscle biopsies: use of p62, LC3 and LAMP2 immunohistochemistry
Elisa Vittonatto, Silvia Boschi, Loredana Chiarò-Piat, Valentina Ponzalino, Sara Bortolani, Chiara Brusa, Innocenzo Rainero, Federica Ricci, Liliana Vercelli and Tiziana Mongini ........................................ 191

Study of anti-Müllerian hormone levels in patients with Myotonic Dystrophy Type 1. Preliminary results
Manuela Ergoli, Massimo Venditti, Raffaele Dotolo, Esther Picillo, Sergio Minucci and Luisa Politano .................. 199

The multifaceted clinical presentation of VCP-proteinopathy in a Greek family
George K. Papadimas, George P. Paraskevas, Thomas Zambelis, Chrisostomos Karagiouris, Mara Bourbouli, Anastasia Bougea, Maggie C. Walter, Nicolas U. Schumacher, Sabine Krause and Elisabeth Kapaki ........................................ 203

Three new cases of dilated cardiomyopathy caused by mutations in LMNA gene
Larysa S. Svititskaya, Nina G. Danilenko, Tatiana Vaikhanakaya, Tatsiyana V. Kurushka and Oleg G. Davydenko ........................................ 207

CASE REPORTS
Is the epicardial left ventricular lead implantation an alternative approach to percutaneous attempt in patients with Steinert disease? A case report
Andrea Antonio Papa, Anna Rago, Roberta Petillo, Paola D’Ambrosio, Marianna Scutieri, Marisa De Feo, Ciro Maiello and Alberto Palladino .................. 213

Complete resolution of left atrial appendage thrombosis with oral dabigatran etexilate in a patient with Myotonic Dystrophy type 1 and atrial fibrillation
Anna Rago, Andrea Antonio Papa, Giulia Arena, Marco Mosella, Antonio Cassese, Alberto Palladino and Paolo Golino .................. 218

OBITUARY
Professor Giovanni Nigro
Luisa Politano and Vincenzo Nigro ........................................... 223

NEWS FROM AROUND THE WORLD
AIM ............................................. 225
MSM ........................................... 225
WMS ........................................... 225

FORTHCOMING MEETINGS .................. 226

Volume XXXVI - CONTENTS ........................................... 236
Volume XXXVI - AUTHOR INDEX .................. 238
Volume XXXVI - SUBJECT INDEX .................. 242
Volume XXXVI - LIST OF REFEREES CONSULTED IN 2017 ........................................... 243

Instructions for Authors ........................................... 245

237
# VOLUME XXXVI - AUTHOR INDEX

## A
- Abiusi E., 99
- Accardi F., 100
- Agazzi E., 82
- Agiennouz M., 82
- Albamonte E., 115
- Alessandri D., 103
- Alfano L., 73
- Ali G., 81, 97, 105
- Aliverti A., 93
- Allegricori L., 108
- Altamura C., 70, 82, 94
- Amati A., 83
- Andreani M., 74
- Angelini C., 19, 41, 72, 74, 77, 94, 114
- Angeloni A., 89
- Annunziata A., 93
- Antonini G., 74, 77, 90, 93, 95, 102
- Ardissone A., 28, 71, 115
- Arena G., 218
- Armarioli A., 70, 75, 83, 99, 107
- Arnoldi M.T., 83
- Arpa G., 86
- Arigo R., 98
- Arrigoni F., 112
- Arrunzilli M., 77
- Assereto S., 111
- Asta G., 19, 41, 68, 95, 98, 107, 115
- Athanasiou D., 73

## B
- Baldacci J., 68
- Balanzani S., 102, 110, 115
- Balligand C., 151
- Balotti U., 19, 41
- Baranello G., 67, 71, 83, 103, 107, 115
- Baratto S., 111
- Barbone F., 90
- Barca E., 68, 96
- Barcellona C., 78, 80, 84, 86, 90, 95
- Baronechelli C., 81, 87, 89
- Barp A., 84
- Barresi R., 76, 84
- Barton P.J.R., 76
- Basta I., 14
- Bastianello S., 103
- Battazza A., 67, 83, 85
- Battini R., 19, 41, 67, 98, 115
- Battisti C., 98, 107
- Bella C., 78
- Bellacchio E., 92
- Bellanova M.F., 100
- Bello L., 19, 41, 67, 84
- Bembi B., 74
- Benedetti S., 76
- Benna P., 102
- Berardinelli A., 3, 19, 41, 67, 69, 77, 85, 103, 106, 107, 115
- Bernardo D., 89, 104, 108
- Bernasconi P., 28, 70, 71, 97
- Bertini E., 67, 69, 72, 74, 75, 76, 84, 87, 89, 92, 95, 99, 106, 107, 114, 115, 125
- Bertoldo A., 112
- Bertoli S., 67, 83, 85
- Beshiri F., 94
- Bianchi M.L.E., 95
- Bianco A., 163
- Biasini F., 88, 85, 100
- Bigoni S., 98
- Bisceglia L., 163
- Bisoldi C., 85
- Blasevich F., 79
- Bohm J., 91
- Bonanno C., 78, 86
- Bonetti A.M., 87
- Bonne G., 76
- Bonuocchi U., 90
- Borgeone E., 86
- Bortolan S., 191
- Bortolotto C., 103
- Boscheti E., 106
- Boschi S., 191
- Bosi F., 86
- Botta A., 95, 109
- Bougea A., 203
- Bouroulle M., 203
- Bovolenta M., 70
- Bracalente I., 107
- Bragato C., 79
- Brais G., 112
- Brand T., 76
- Bresolin N., 72
- Brighina E., 19, 41
- Brighina F., 88
- Brignon E., 93
- Brisca G., 68
- Brizi T., 68, 85, 91, 98, 100
- Broda P., 68, 80, 92, 111
- Brugnoli R., 28
- Bruno C., 67, 68, 71, 72, 74, 78, 92, 98, 107, 111, 114, 115
- Bruno G., 108
- Brusa C., 106, 191
- Brusa R., 96
- Buco E., 77, 90, 93, 95
- Buchan R., 76
- Buldini B., 75
- Bushby K., 73

## C
- Cabona C., 94
- Calandriello L., 75
- Caldarazzo Iancu E., 85, 114
- Calc L., 81
- Callada F., 103
- Camerino G.M., 83, 88
- Campadello P., 84
- Campbell C., 115
- Canioni E., 71
- Cantello R., 104
- Cao M., 77
- Capello G.L., 100
- Capet N., 87
- Capogrossi R.F., 83
- Caporali L., 106, 112
- Capozzi A.R., 100
- Carbone N., 76
- Cardani R., 85, 86, 93, 105
- Carducci C., 89
- Carfeli V., 106, 112, 114
- Carri S., 90
- Carli F., 71, 81, 87, 89, 96, 114
- Carlesi A., 87
- Carlini F., 102
- Carlini G., 96
- Carlucci A., 105
- Carotti M., 78
- Casalini C., 95
- Casiraghi J., 115
- Cassandri D., 67, 68, 80, 81, 85, 105, 107
- Cassese A., 218
- Castelletti S., 135
- Castello F., 86
- Castino V., 70, 108
- Catalano A., 78
- Catarzi S., 101
- Catteruccia M., 19, 41, 67, 87
- Caumo L., 84
- Cavallaro F., 100, 110
- Cavallaro N., 102
- Cavali M., 93
- Cavicchi C., 100
- Cecchi A., 100
- Celle E., 71
- Cenci G., 88, 100, 105, 106
- Centofanti F., 109
- Cerina A., 103
- Chardon K., 112
- Chiaradì-Piat L., 191
- Chico L., 76, 97, 105
- Chirzanowski S.M., 151
- Cicchi A., 88
- Circari A., 98
- Ciranni A.M., 82

## D
- D’Adamo M.C., 94
- D’Agruma L., 163
- D’Ambrosio P., 89, 101, 213
- D’Amico A., 19, 41, 67, 69, 72, 75, 76, 84, 87, 92, 95, 99, 107, 115, 125
- D’Angel G., 77, 115
- D’Angel M.G., 19, 41, 67, 93, 109, 112
- D’Angelo R., 88, 106
- Dansker J., 73
- Danesino C., 105
- Danesino C.1, 69
- Daniels M.J., 151
- Danilenko N.G., 207
- Danilotti M., 101
- Davis R., 73
- Davydov O.G., 207
- De Amici R., 67, 83, 85
- De Biaggi M.L., 115
- De Bleecker J., 72
- De Foe M., 213
M
Madia F., 71, 94, 111
Maestrri E., 94, 115
Maestrri M., 90, 97
Maggi L., 69, 70, 71, 72, 74, 76, 77, 79, 109
Magliano L., 19, 41
Magnano G.M., 68
Magri F., 67, 69, 72, 75, 96, 112
Maiello C., 213
Maioli M.A., 69, 76, 77, 103, 107
Maiorca M., 109
Malandrini A., 69, 91, 98, 107
Malaffi E., 67, 69, 75, 76, 90, 92, 102, 113, 114
Mallor E., 70, 108
Mondello S., 74
Monforte M., 97
Montagnese F., 74
Montano V., 81, 97
Moody S., 91
Mora M., 67, 69, 70, 71, 72, 75, 79
Morabito N., 78
Mora M., 67, 69, 70, 71, 72, 74, 75, 76, 77, 103, 106, 107, 114, 115, 191
Montanari A., 76
Morini F., 90
Mortari A., 94
Moscatelli, M., 82
Moselli M., 218
Mottarino F., 75
Mourino L., 96
Morino S., 90, 93
Moro F., 67, 98
Moroni I., 28, 90, 91, 92, 96, 98, 114
Musumeci O., 68, 69, 71, 72, 74, 80, 91, 92, 96, 98, 114
Musumeci S.A., 86
M N
Nagaraju K., 73
Nagel A.M., 2
Negri L., 178
Nelson K.R., 125
Neri M., 75, 94, 98, 99, 111
Nicchia G.P., 88
Nicoccia G., 78, 90, 95
Niccolotti O., 94
Nigro G., 91
Nigro V., 68, 72, 77, 80, 81, 91, 92, 101, 109, 223
Nikolic A., 77
Nizzardo M., 72, 75
Nobili F.M., 71
Novelli A., 101
Novelli G., 95, 109
O
Oggiano L., 87
Ong T., 69
Orcini C., 101
Orcucci D., 114
Osman H., 70, 75, 83, 99
Oteri R., 82
P
Paci E., 94
Padovani A., 71, 81, 87, 89, 94, 96, 114
Pagliarani S., 96, 102
Pagliarini V., 106
Palo, 86, 88
Palermo C., 99
Palladino F., 101, 213, 218
Pameo M., 19, 41, 67, 69, 75, 99, 107, 115
Pantazis A.A., 135
Papa A.A., 101, 213, 218
Papa V., 88, 100
Papadimas G.K., 203
Paraskevas G.P., 203
Panici P., 100
Pasquini E., 100, 101, 107
Passamonti E., 68, 71, 78, 84
Pegoraro V., 94
Pellegri C., 112
Pellizzoni M., 108
Peltz S.W., 69
Pennisi E.M., 67, 80, 82, 84, 85, 88, 91, 92, 101, 109, 223
Perini G., 70
Peric S., 14
Perini G., 70
Pesce V., 14
Pesch M., 94
Petrillo R., 89, 101, 213
Petrucci A., 81, 95, 98
Petrucci P., 163
Petty R., 84
Peverelli L., 69, 71, 80, 96, 112
Pichiecchio A., 85, 103
Piccolo I., 89, 199
Pietrantuana V., 106
Pietra M., 88
Pietrini V., 100
Pigo D., 75
Piluso G., 72
Pini A., 67, 75, 98, 103, 107, 109, 115
Pinna A.D., 106
Pinto-Basto J., 178
Pira R., 71, 76, 103
Pironi L., 106
Pizzamiglio C., 104
Placento V., 106
Poli C., 103
Polito F., 82
Pompeo E., 74
Ponzalino V., 191
Portaro S., 77, 100
Pozzi M., 109
Pozzolini G., 71
Previtali S.C., 71, 109
Primiano G., 73, 89, 104, 108, 114
Profazio C., 78, 86
Proietti C., 102
Provinciali L., 96
Pugliati P., 90
R
Racca F., 78
Raciti M.V., 103
Ragni L., 109
Rago A., 213, 218
Raineri I., 191
Rakocevic-Stojanovic V., 14
Ranalli D., 99
Rao F., 70, 108
Rastelli E., 74, 81, 95, 104, 113
Ravagni S., 69, 71, 74, 105
Ravani A., 75
Recupero A., 90
Renard D., 87
Renna L.V., 86, 105
Ricci E., 73, 97
Ricci F., 67, 106, 115, 191
Ricci G., 19, 41, 69, 76, 77, 81, 97, 102, 105, 110
Riccitelli R., 90, 97
Richard I., 112
Riebling P., 69
Rimesi P., 75, 110, 111
Rinaldi R., 88, 106
Rinaldi P., 75, 110, 111
Rochetti R., 75
Riva R., 82
Rizzo E., 110
Rizzo S., 90
Robbiano A., 71
Rodolico C., 68, 69, 76, 77, 80, 82, 84, 85, 88, 91, 92, 96, 100, 107, 115
Rolle L., 106
Roma E., 70, 108
Romano C., 78, 113
Romeo C., 86
Romero N.B., 91
240
Roos A., 1, 2, 76
Rosellini G., 108
Rossi F., 106
Rossi M., 85, 103
Rossi R., 70, 75, 76, 83, 99, 107, 110
Rosti C., 103
Rota S., 71, 81, 87, 89, 96, 114
Rottoli M.R., 82
Rousseau M., 81
Rubezhi A., 66, 77, 98, 107
Ruggieri A., 71, 79
Ruggieri M., 113
Ruggiero L., 69, 72, 77
Russo A., 93, 112
Russo L., 163
Russo M., 84
Russo S., 109

S
Saccani E., 100
Sacchetti R., 78
Sacchini M., 69, 71, 100, 101
Sacconi S., 87
Sagliono A., 19, 41
Sahboni D., 82, 94
Sala S., 93
Salani S., 72, 75
Salvatore S., 107
Sampaolo S., 108
Sancricca C., 71, 89, 104, 108
Sandinà D., 78
Sannicolo G., 70, 108
Sansone V., 75, 108
Sansone V.A., 70, 94, 115
Santa Paola S., 86
Santorelli F.M., 67, 68, 72, 77, 80, 81, 85, 95, 98, 103, 107, 114
Santoro L., 69, 72, 76, 77, 107
Santoro M., 109
Saraceno L., 105
Saredi S., 71, 79
Saucelli D., 89, 104, 108
Savarese M., 68, 72, 77, 80, 81, 91, 112
Savasta S., 71
Savic-Pavicic D., 14
Savio M., 86
Scalco R., 106
Scalise R., 19, 41
Scariati M., 109
Scarpetta P., 93
Scarpini G., 109
Schenone A., 71
Schiaffino M.C., 71
Schlemmer H.-P., 2
Schmalfruss I., 151
Schols L., 99
Schoser B., 77
Schumacher N.U., 203
Schwartz E., 83
Sciacco M., 80, 102, 113
Scilocci C., 113
Scolamiero M., 101
Scotti C., 69
Scotton C., 70, 75, 76, 83, 98, 99, 107
Scuderi C., 86
Scutiferò M., 19, 41, 89, 101, 213
Seidita F., 102
Selvatici R., 75, 98, 99, 110, 111
Semplicini C., 19, 41, 67, 71, 84
Senderek J., 76
Senesac C., 151
Sera F., 77
Serlenga L., 83
Servidei S., 71, 73, 74, 89, 104, 108, 114
Sframelli M., 19, 41, 67, 78, 84, 88, 90, 92, 95, 110
Siciliano G., 25, 69, 70, 71, 74, 77, 81, 85, 97, 102, 103, 105, 110, 114, 115, 125
Silvestri G., 73, 95, 109
Simoni A., 69
Simioncini C., 25, 81, 97, 110
Simons D., 2
Sivitskaya L.N., 207
Smith A., 73
Soardi M., 78
Sollara V., 104
Solla E., 76, 103
Sorrentino V., 105
Souza M., 69
Spaans F., 125
Spada M., 106
Stancanelli C., 110
Storbeck P., 98
Storch K., 73
Stramare R., 84
Straub V., 76, 77
T
Tacchetti R., 78
Taglia I., 107
Tainera M., 72
Tartaglia M., 92, 104
Tartara E., 102
Tasca G., 73, 92, 97, 112
Tavoni A., 81
Telese R., 71, 77, 90, 111
Terracciano C., 74, 95, 113
Terranova C., 110
Terzaghi M., 102
Testi M., 74
Tettamanti A., 109
Timmerman V., 98
Tironi R., 80, 85, 102, 113
Tiziano F.D., 99
Tognoni G., 25
Tomelleri G., 77
Tonin P., 69, 71, 74, 75, 114
Tonon C., 88
Topf A., 77
Torella A., 72, 77, 91, 92, 101
Toscano A., 68, 69, 71, 72, 74, 80, 82, 85, 91, 92, 96, 98, 100, 114, 115
Trabaneli C., 75, 107, 110, 111
Trabatti C., 71
Traverso M., 111
Tretroli P., 163
Trifillis P., 69
Trojano M., 83
Trovato R., 68, 98, 107
Trucco F., 68, 71, 78
Tugnoli V., 98
Tupler R., 77, 111
Turutto F., 87
U
Ubaldi U., 102
Udd B., 77, 97, 112
V
Valkhanskaya T.G., 207
Valaperta R., 85, 93
Valentino L., 109
Valentino M.L., 112
Valle M., 68
Vanacore N., 95
Vandenborn K., 151
Vanoli F., 90
Vavla M., 74
Velardo D., 109, 112
Venditti M., 199
Venturiolli A., 107, 111
Verardo M., 89, 92
Vercelli L., 72, 76, 77, 114, 191
Verga L., 100
Versaci A., 86
Vezyroglou K., 98
Vianello A., 102
Vihola A., 112
Villa L., 77, 80, 102, 113
Vischer A.S., 135
Vita G., 19, 41, 68, 75, 78, 82, 84, 86, 90, 95, 100, 110, 115
Vita G.L., 19, 41, 78, 82, 84, 86, 90, 95, 110
Vitaliti G., 113
Vitello G.A., 86
Vitello B., 106
Vittonatto E., 191
Vizzacaro E., 90, 93, 104, 113
Vroom E., 73
Vujnic M., 14
W
Walsh R., 76
Walter G.A., 151
Walter M.C., 203
Weber M.-A., 2
Wenninger S., 74
Wenzel A., 78
Wissner M., 76
Willcocks R.J., 151
Wirth B., 98, 99
Woods A.M., 113
Z
Zaccaro A., 19, 41
Zambello T., 203
Zanato R., 84
Zanini R., 83
Zanolini A., 94, 115
Zanotti S., 79
Zara F., 71, 94, 111
Zeviani M., 114
Ziegler A.E., 2
Zoni L., 103
Zoppo M., 106
<table>
<thead>
<tr>
<th>Term</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>23Na MRI</td>
<td>2</td>
</tr>
<tr>
<td>adPEO</td>
<td>25</td>
</tr>
<tr>
<td>ALS</td>
<td>203</td>
</tr>
<tr>
<td>ANT1</td>
<td>25</td>
</tr>
<tr>
<td>Anti-Müllerian hormone</td>
<td>199</td>
</tr>
<tr>
<td>Arrhythmogenic right ventricular dysplasia/ cardiomyopathy</td>
<td>135</td>
</tr>
<tr>
<td>Atrial fibrillation</td>
<td>218</td>
</tr>
<tr>
<td>Atrial thrombus</td>
<td>218</td>
</tr>
<tr>
<td>Autophagy</td>
<td>191</td>
</tr>
<tr>
<td>Bethlem myopathy</td>
<td>178</td>
</tr>
<tr>
<td>Cardiac resynchronization</td>
<td>213</td>
</tr>
<tr>
<td>CHRNE gene</td>
<td>28</td>
</tr>
<tr>
<td>Cognitive impairment</td>
<td>25</td>
</tr>
<tr>
<td>Collagen VI</td>
<td>178</td>
</tr>
<tr>
<td>Compulsive</td>
<td>14</td>
</tr>
<tr>
<td>Congenital muscular dystrophy</td>
<td>178</td>
</tr>
<tr>
<td>Congenital myasthenic syndromes</td>
<td>28</td>
</tr>
<tr>
<td>Costs for care</td>
<td>41</td>
</tr>
<tr>
<td>Dabigatran etexilate</td>
<td>218</td>
</tr>
<tr>
<td>Dementia</td>
<td>203</td>
</tr>
<tr>
<td>Dilated cardiomyopathy</td>
<td>207</td>
</tr>
<tr>
<td>Duchenne</td>
<td>2</td>
</tr>
<tr>
<td>Duchenne Muscular Dystrophy</td>
<td>151</td>
</tr>
<tr>
<td>Emery-Dreifuss muscular dystrophy</td>
<td>207</td>
</tr>
<tr>
<td>Epicardial left ventricular implantation</td>
<td>213</td>
</tr>
<tr>
<td>Eplerenone</td>
<td>2</td>
</tr>
<tr>
<td>Gonadal function</td>
<td>199</td>
</tr>
<tr>
<td>Heteroplasmy</td>
<td>163</td>
</tr>
<tr>
<td>Holter electrocardiography</td>
<td>135</td>
</tr>
<tr>
<td>Homoplasmy</td>
<td>163</td>
</tr>
<tr>
<td>Immunohistochemistry</td>
<td>191</td>
</tr>
<tr>
<td>Inclusion body myopathy</td>
<td>191</td>
</tr>
<tr>
<td>Integrated care</td>
<td>19</td>
</tr>
<tr>
<td>LHON</td>
<td>163</td>
</tr>
<tr>
<td>Limb-girdle muscular dystrophy</td>
<td>207</td>
</tr>
<tr>
<td>Lung function</td>
<td>33</td>
</tr>
<tr>
<td>Magnetic resonance imaging</td>
<td>151</td>
</tr>
<tr>
<td>Mitochondrial dementia</td>
<td>25</td>
</tr>
<tr>
<td>Mitochondrial disease</td>
<td>25</td>
</tr>
<tr>
<td>Mitochondrial DNA mutation</td>
<td>163</td>
</tr>
<tr>
<td>Mouthpiece ventilation</td>
<td>33</td>
</tr>
<tr>
<td>mtDNA copy number</td>
<td>163</td>
</tr>
<tr>
<td>Muscular and respiratory tract diseases</td>
<td>125</td>
</tr>
<tr>
<td>Muscular dystrophies</td>
<td>19, 41</td>
</tr>
<tr>
<td>Myotendinous junction</td>
<td>151</td>
</tr>
<tr>
<td>Myotonic dystrophy</td>
<td>218</td>
</tr>
<tr>
<td>Myotonic dystrophy type 1</td>
<td>199</td>
</tr>
<tr>
<td>Myotonic dystrophy type 2</td>
<td>14</td>
</tr>
<tr>
<td>Necrotizing myopathy</td>
<td>191</td>
</tr>
<tr>
<td>Neonate</td>
<td>125</td>
</tr>
<tr>
<td>Not invasive nasal ventilation</td>
<td>33</td>
</tr>
<tr>
<td>Paranoid</td>
<td>14</td>
</tr>
<tr>
<td>Personality</td>
<td>14</td>
</tr>
<tr>
<td>Pharmacological treatment</td>
<td>19</td>
</tr>
<tr>
<td>Phenotype variability</td>
<td>28</td>
</tr>
<tr>
<td>Pompe disease</td>
<td>191</td>
</tr>
<tr>
<td>Psycho-social treatments</td>
<td>41</td>
</tr>
<tr>
<td>Quality of life</td>
<td>14</td>
</tr>
<tr>
<td>Rehabilitative intervention</td>
<td>19</td>
</tr>
<tr>
<td>Steinert disease</td>
<td>33, 213</td>
</tr>
<tr>
<td>Stridor</td>
<td>125</td>
</tr>
<tr>
<td>VCP</td>
<td>203</td>
</tr>
<tr>
<td>Ventricular tachycardia</td>
<td>135</td>
</tr>
</tbody>
</table>
VOLUME XXXVI - LIST OF REFEREES CONSULTED IN 2017

Angelini, Corrado
Argov, Zohar
Battini, Roberta
Desaphy, Jean-François
Diodato, Daria
Fossati, Babara
Godard-Bauché, Stéphanie
Maggi, Lorenzo
Mancuso, Michelangelo
Massa, Roberto
Milone, Margherita
Mora, Marina
Nigro, Vincenzo
Nesti, Claudia
Paciello, Orlando
Plantedosi, Diego
Previtali, Stefano
Rodolico, Carmelo
Sansone, Valeria
Santorelli, Filippo Maria
Tasca, Giorgio
Todisco, Vincenzo
Troisi, Francesca
Wöhrle, Johannes
For application or renewal to MSM

MEDITERRANEAN SOCIETY OF MYOLOGY* (MSM)
H. Topaloglu, President
L.T. Middleton, G. Siciliano, Vice-Presidents
K. Christodoulou, Secretary
L. Politano, Treasurer

APPLICATION/RENEWAL FORM

Application/Renewal for 1yr 2 yrs

☑ ☐

Prof. Luisa Politano, MSM Treasurer, Viale dei Pini 101, 80131, Napoli, Italy
Fax: 39 081 5665100 E-mail: actamyologica@gmail.com • luisa.politano@unicampania.it
Fax or Mail to the above address. Type or print.

Name ___________________________________________ Degree(s) ______________
First
Last

Department ____________________________________________________________

Institution ___________________________________________________________

Street Address ________________________________________________________

City, State, zip, country ________________________________________________

Tel (__________) ___________________ Fax (__________) ___________________
Area code Area code

* Amount payable: 1 year Euro 100
2 years Euro 150

☐ I enclose copy of the bank transfer to:

Bank name: Banco di Napoli – Filiale 00660
Bank address: Via Riviera di Chiaia, 131 – 80122 Napoli, Italy
Account holder: MSM – Mediterranean Society of Myology
IBAN code: IT48T0101003488100000100680
BIC code (for foreign countries): IBSPITNA
INSTRUCTIONS FOR AUTHORS

Acta Myologica publishes articles related to research in and the practice of primary myopathies, cardiomyopathies and neuromyopathies, including observational studies, clinical trials, epidemiology, health services and outcomes studies, and advances in applied (translational) and basic research. Manuscripts are examined by the editorial staff and usually evaluated by expert reviewers assigned by the editors. Both clinical and basic articles will also be subject to statistical review, when appropriate. Provisional or final acceptance is based on originality, scientific content, and topical balance of the journal. Decisions are communicated by email, generally within eight weeks. All rebuttals must be submitted in writing to the editorial office.

On-line submission

Manuscript submission must be effected on line: www.actamyologica.it according to the following categories:

**Original articles** (maximum 5000 words, 8 figures or tables). A structured abstract of no more than 250 words should be included.

**Reviews, Editorials** (maximum 4000 words for Reviews and 1600 words for Editorials). These are usually commissioned by the Editors. Before spontaneously writing an Editorial or Review, it is advisable to contact the Editor to make sure that an article on the same or similar topic is not already in preparation.

**Case Reports, Scientific Letters** (maximum 1500 words, 10 references, 3 figures or tables, maximum 4 authors). A summary of 150 words may be included.

**Letters to the Editor** (maximum 600 words, 5 references). Letters commenting upon papers published in the journal during the previous year or concerning news in the myologic, cardio-myologic or neuro-myologic field, will be welcome. All Authors must sign the letter.

**Rapid Reports** (maximum 400 words, 5 references, 2 figures or tables). A letter should be included explaining why the author considers the paper justifies rapid processing.

**Lecture.** Invited formal discourse as a method of instruction. The structure will be suggested by the Editor.

**Congress Proceedings** either in the form of Selected Abstracts or Proceedings will be taken into consideration.

Information concerning new books, congresses and symposia, will be published if conforming to the policy of the Journal. The manuscripts should be arranged as follows: 1) Title, authors, address institution, address for correspondence; 2) Repeat title, abstract, key words; 3) Text; 4) References; 5) Legends; 6) Figures or tables. Pages should be numbered (title page as page 1).

**Title page.** Check that it represents the content of the paper and is not misleading. Also suggest a short running title.

**Key words.** Supply up to three key words. Wherever possible, use terms from Index Medicus – Medical Subject Headings.

**Text.** Only international SI units and symbols must be used in the text. Tables and figures should be cited in numerical order as first mentioned in the text. Patients must be identified by numbers not initials.

**Illustrations.** Figures should be sent in .jpeg or .tiff format. Legends should be typed double-spaced and numbered with Arabic numerals corresponding to the illustrations. When symbols, arrows, numbers, or letters are used to identify parts of the illustrations, each should be explained clearly in the legend. For photomicrographs, the internal scale markers should be defined and the methods of staining should be given. If the figure has been previously published a credit line should be included and permission in writing to reproduce should be supplied. Colour photographs can be accepted for publication, the cost to be covered by the authors.

**PATIENTS IN PHOTOGRAPHS ARE NOT TO BE RECOGNISABLE**

**Tables.** Tables should be self-explanatory, double spaced on separate sheets with the table number and title above the table and explanatory notes below. Arabic numbers should be used for tables and correspond with the order in which the table is first mentioned in the text.

**References.** Reference numbers in the text must be in brackets. References in the list must be numbered as they appear in the text.


**Congress Proceedings** either in the form of Selected Abstracts or Proceedings will be taken into consideration.

**Lectura** considers the paper justifies rapid processing.

**Letters to the Editor** (maximum 600 words, 5 references). Letters commenting upon papers published in the journal during the previous year or concerning news in the myologic, cardio-myologic or neuro-myologic field, will be welcome. All Authors must sign the letter.

**Rapid Reports** (maximum 400 words, 5 references, 2 figures or tables). A letter should be included explaining why the author considers the paper justifies rapid processing.

**Lecture.** Invited formal discourse as a method of instruction. The structure will be suggested by the Editor.

**Congress Proceedings** either in the form of Selected Abstracts or Proceedings will be taken into consideration.

Information concerning new books, congresses and symposia, will be published if conforming to the policy of the Journal. The manuscripts should be arranged as follows: 1) Title, authors, address institution, address for correspondence; 2) Repeat title, abstract, key words; 3) Text; 4) References; 5) Legends; 6) Figures or tables. Pages should be numbered (title page as page 1).

**Title page.** Check that it represents the content of the paper and is not misleading. Also suggest a short running title.

**Key words.** Supply up to three key words. Wherever possible, use terms from Index Medicus – Medical Subject Headings.

**Text.** Only international SI units and symbols must be used in the text. Tables and figures should be cited in numerical order as first mentioned in the text. Patients must be identified by numbers not initials.

**Illustrations.** Figures should be sent in .jpeg or .tiff format. Legends should be typed double-spaced and numbered with Arabic numerals corresponding to the illustrations. When symbols, arrows, numbers, or letters are used to identify parts of the illustrations, each should be explained clearly in the legend. For photomicrographs, the internal scale markers should be defined and the methods of staining should be given. If the figure has been previously published a credit line should be included and permission in writing to reproduce should be supplied. Colour photographs can be accepted for publication, the cost to be covered by the authors.

**PATIENTS IN PHOTOGRAPHS ARE NOT TO BE RECOGNISABLE**

**Tables.** Tables should be self-explanatory, double spaced on separate sheets with the table number and title above the table and explanatory notes below. Arabic numbers should be used for tables and correspond with the order in which the table is first mentioned in the text.

**References.** Reference numbers in the text must be in brackets. References in the list must be numbered as they appear in the text.


Please check each item of the following checklist before mailing:

- Three index terms, short title for running head (no more than 40 letter spaces) on the title page.
- Name(s) of the author(s) in full, name(s) of institution(s) in the original language, address for correspondence with telephone and fax numbers and email address on the second page.
- Summary (maximum 250 words).
- References, tables and figures cited consecutively as they appear in the text.
- Figures submitted actual size for publication (i.e., 1 column wide or 2 columns wide).
- Copyright assignment and authorship responsibility signed (with date) by all Authors.
- References prepared according to instructions.
- English style.
- Patients in photographs not recognisable.

The editor remains at the complete disposal of those with rights whom it was impossible to contact, and for any omissions.

Photocopies, for personal use, are permitted within the limits of 15% of each publication by following payment to SIAE of the charge due, article 68, paragraphs 4 and 5 of the Law April 22, 1941, No 633.

Reproductions for professional or commercial use or for any other other purpose other than personal use can be made following a written request and specific authorization in writing from AIDRO, Corso di Porta Romana, 108, 20122 Milan, Italy. E-mail: segreteria@aidro.org and web site: www.aidro.org.